[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 72 of about 72
1. Albitar M, Potts SJ, Giles FJ, O'Brien S, Keating M, Thomas D, Clarke C, Jilani I, Aguilar C, Estey E, Kantarjian H: Proteomic-based prediction of clinical behavior in adult acute lymphoblastic leukemia. Cancer; 2006 Apr 1;106(7):1587-94
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Proteomic-based prediction of clinical behavior in adult acute lymphoblastic leukemia.
  • BACKGROUND: Response in adult acute lymphoblastic leukemia (ALL) can be achieved in a majority of patients.
  • However, unlike pediatric ALL, recurrence is common in adult ALL, and the ability to predict at an early stage which patients are most likely to experience recurrence may help in devising new therapeutic approaches to prevent recurrence.
  • [MeSH-major] Decision Trees. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology. Proteomics
  • [MeSH-minor] Adolescent. Adult. Age Factors. Aged. Child, Preschool. Female. Humans. Male. Middle Aged. Predictive Value of Tests. Prognosis. Protein Array Analysis. Recurrence

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2006 American Cancer Society.
  • (PMID = 16518825.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


2. Chiaretti S, Guarini A, De Propris MS, Tavolaro S, Intoppa S, Vitale A, Iacobelli S, Elia L, Ariola C, Ritz J, Foà R: ZAP-70 expression in acute lymphoblastic leukemia: association with the E2A/PBX1 rearrangement and the pre-B stage of differentiation and prognostic implications. Blood; 2006 Jan 1;107(1):197-204
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] ZAP-70 expression in acute lymphoblastic leukemia: association with the E2A/PBX1 rearrangement and the pre-B stage of differentiation and prognostic implications.
  • We evaluated the expression of 2 members of the Syk family, ZAP-70 and Syk, in acute lymphoblastic leukemia (ALL) samples, using data derived from a series of 33 T-ALL and 95 B-lineage adult ALL patients analyzed by oligonucleotide arrays.
  • In ALL, ZAP-70 expression is associated with the E2A/PBX1 rearrangement and pre-B stage and may have a prognostic role and be a candidate molecule for targeted therapies.
  • [MeSH-major] Gene Expression Regulation, Neoplastic. Homeodomain Proteins / genetics. Oncogene Proteins, Fusion / genetics. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / pathology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. ZAP-70 Protein-Tyrosine Kinase / genetics
  • [MeSH-minor] Adult. Cell Differentiation. Child. Enzyme Precursors / genetics. Follow-Up Studies. Gene Expression Profiling. Gene Rearrangement. Humans. Immunoglobulin mu-Chains. Intracellular Signaling Peptides and Proteins. Prognosis. Protein-Tyrosine Kinases / genetics. Recurrence

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16160012.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Enzyme Precursors; 0 / Homeodomain Proteins; 0 / Immunoglobulin mu-Chains; 0 / Intracellular Signaling Peptides and Proteins; 0 / Oncogene Proteins, Fusion; 146150-85-8 / E2A-Pbx1 fusion protein; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.1 / Syk kinase; EC 2.7.10.2 / ZAP-70 Protein-Tyrosine Kinase
  •  go-up   go-down


3. Weng AP, Millholland JM, Yashiro-Ohtani Y, Arcangeli ML, Lau A, Wai C, Del Bianco C, Rodriguez CG, Sai H, Tobias J, Li Y, Wolfe MS, Shachaf C, Felsher D, Blacklow SC, Pear WS, Aster JC: c-Myc is an important direct target of Notch1 in T-cell acute lymphoblastic leukemia/lymphoma. Genes Dev; 2006 Aug 1;20(15):2096-109
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] c-Myc is an important direct target of Notch1 in T-cell acute lymphoblastic leukemia/lymphoma.
  • Human acute T-cell lymphoblastic leukemias and lymphomas (T-ALL) are commonly associated with gain-of-function mutations in Notch1 that contribute to T-ALL induction and maintenance.
  • Additionally, we show that primary murine thymocytes at the DN3 stage of development depend on ligand-induced Notch signaling to maintain c-myc expression.

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Lymphoblastic lymphoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cell. 2005 Aug 12;122(3):435-47 [16096062.001]
  • [Cites] Nat Immunol. 2005 Sep;6(9):881-8 [16056227.001]
  • [Cites] J Exp Med. 2005 Oct 17;202(8):1037-42 [16230473.001]
  • [Cites] Immunity. 1999 Sep;11(3):299-308 [10514008.001]
  • [Cites] J Exp Med. 1999 Oct 18;190(8):1039-48 [10523602.001]
  • [Cites] Curr Biol. 2005 Jan 26;15(2):94-104 [15668164.001]
  • [Cites] Nat Immunol. 2005 Mar;6(3):314-22 [15665828.001]
  • [Cites] Nat Cell Biol. 2005 Mar;7(3):303-10 [15723053.001]
  • [Cites] Nat Cell Biol. 2005 Mar;7(3):311-8 [15723054.001]
  • [Cites] Nat Cell Biol. 2005 Mar;7(3):295-302 [15723055.001]
  • [Cites] Nat Med. 2000 Nov;6(11):1278-81 [11062542.001]
  • [Cites] Nat Genet. 2000 Dec;26(4):484-9 [11101851.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Jan 2;98(1):31-6 [11134512.001]
  • [Cites] Nat Immunol. 2001 Apr;2(4):307-15 [11276201.001]
  • [Cites] Mol Cell Biol. 2001 Sep;21(17):5925-34 [11486031.001]
  • [Cites] Nat Med. 2002 Jan;8(1):68-74 [11786909.001]
  • [Cites] Genes Dev. 2002 Feb 1;16(3):295-300 [11825871.001]
  • [Cites] Cancer Cell. 2002 Feb;1(1):75-87 [12086890.001]
  • [Cites] Mol Cell Biol. 2006 Jan;26(1):209-20 [16354692.001]
  • [Cites] Blood. 2006 Jan 15;107(2):781-5 [16166587.001]
  • [Cites] Immunity. 2006 Jan;24(1):53-64 [16413923.001]
  • [Cites] J Biol Chem. 2006 Feb 24;281(8):5106-19 [16365048.001]
  • [Cites] Blood. 2006 Mar 15;107(6):2540-3 [16282337.001]
  • [Cites] Mol Cell Biol. 2006 Jun;26(12):4642-51 [16738328.001]
  • [Cites] Annu Rev Cell Dev Biol. 2000;16:653-99 [11031250.001]
  • [Cites] Curr Biol. 1999 Nov 4;9(21):1255-8 [10556095.001]
  • [Cites] Mol Cell Biol. 2000 Jun;20(11):3831-42 [10805726.001]
  • [Cites] Nature. 2000 May 18;405(6784):364-8 [10830967.001]
  • [Cites] Mol Cell. 2000 Feb;5(2):197-206 [10882062.001]
  • [Cites] Mol Cell. 2000 Feb;5(2):207-16 [10882063.001]
  • [Cites] EMBO J. 2000 Jul 3;19(13):3337-48 [10880446.001]
  • [Cites] Curr Biol. 2000 Jun 29;10(13):R471-3 [10898989.001]
  • [Cites] Immunity. 2000 Jul;13(1):73-84 [10933396.001]
  • [Cites] Blood. 2000 Sep 1;96(5):1906-13 [10961893.001]
  • [Cites] Mol Cell Biol. 2000 Oct;20(20):7505-15 [11003647.001]
  • [Cites] Dev Biol. 1999 Sep 1;213(1):33-53 [10452845.001]
  • [Cites] Mol Cell. 1999 Aug;4(2):199-207 [10488335.001]
  • [Cites] Cell. 1999 Sep 17;98(6):779-90 [10499795.001]
  • [Cites] Immunity. 2002 Jun;16(6):869-79 [12121668.001]
  • [Cites] EMBO J. 2002 Sep 16;21(18):4820-30 [12234922.001]
  • [Cites] Mol Cell Biol. 2003 Jan;23(2):655-64 [12509463.001]
  • [Cites] Biochemistry. 2003 Jan 14;42(1):137-44 [12515548.001]
  • [Cites] Science. 2003 Feb 7;299(5608):887-90 [12574629.001]
  • [Cites] Blood. 2003 Apr 1;101(7):2693-703 [12446444.001]
  • [Cites] Genes Dev. 2003 May 1;17(9):1071-7 [12730130.001]
  • [Cites] Cell Cycle. 2003 May-Jun;2(3):181-4 [12734418.001]
  • [Cites] J Biol Chem. 2003 Jun 6;278(23):21232-9 [12644465.001]
  • [Cites] Cancer Cell. 2003 Jun;3(6):551-64 [12842084.001]
  • [Cites] Nature. 2003 Oct 23;425(6960):841-6 [14574413.001]
  • [Cites] Cancer Cell. 2003 Dec;4(6):451-61 [14706337.001]
  • [Cites] Nat Immunol. 2004 Mar;5(3):247-53 [14985712.001]
  • [Cites] Nat Immunol. 2004 Apr;5(4):410-7 [15034575.001]
  • [Cites] Cell. 2004 May 14;117(4):515-26 [15137944.001]
  • [Cites] Immunity. 2004 May;20(5):611-22 [15142529.001]
  • [Cites] J Biol Chem. 2004 Jun 11;279(24):24986-93 [15067010.001]
  • [Cites] Science. 2004 Oct 8;306(5694):269-71 [15472075.001]
  • [Cites] Mol Cell Biol. 2004 Nov;24(21):9265-73 [15485896.001]
  • [Cites] EMBO J. 1988 Dec 1;7(12):3917-27 [3145200.001]
  • [Cites] Cell. 1991 Aug 23;66(4):649-61 [1831692.001]
  • [Cites] Cancer Res. 1993 Apr 1;53(7):1665-9 [8453639.001]
  • [Cites] Nucleic Acids Res. 1994 Mar 25;22(6):965-71 [8152928.001]
  • [Cites] Cell. 1994 Oct 7;79(1):143-56 [7923373.001]
  • [Cites] Mol Cell Biol. 1994 Dec;14(12):8292-303 [7969165.001]
  • [Cites] Cell. 1995 Oct 20;83(2):289-99 [7585946.001]
  • [Cites] Nature. 1995 Sep 28;377(6547):355-8 [7566092.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Feb 20;93(4):1683-8 [8643690.001]
  • [Cites] J Exp Med. 1996 May 1;183(5):2283-91 [8642337.001]
  • [Cites] Genes Dev. 1996 Aug 1;10(15):1930-44 [8756350.001]
  • [Cites] Development. 1997 Feb;124(4):925-36 [9043073.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Nov 11;94(23):12274-9 [9356439.001]
  • [Cites] Nature. 1998 May 28;393(6683):382-6 [9620803.001]
  • [Cites] Nature. 1999 Apr 8;398(6727):518-22 [10206645.001]
  • [Cites] Nature. 1999 Apr 8;398(6727):522-5 [10206646.001]
  • [Cites] Nature. 1999 Apr 8;398(6727):525-9 [10206647.001]
  • [Cites] Science. 1999 Apr 30;284(5415):770-6 [10221902.001]
  • [Cites] Immunity. 1999 May;10(5):547-58 [10367900.001]
  • [Cites] Nat Cell Biol. 2005 Mar;7(3):215-7 [15738972.001]
  • [Cites] Annu Rev Immunol. 2005;23:945-74 [15771590.001]
  • [Cites] Nat Immunol. 2005 Jul;6(7):671-9 [15951812.001]
  • [Cites] Nat Immunol. 2005 Jul;6(7):663-70 [15951813.001]
  • [Cites] Nat Immunol. 2005 Jul;6(7):680-8 [15991363.001]
  • [ErratumIn] Genes Dev. 2007 Mar 1;21(5):625
  • (PMID = 16847353.001).
  • [ISSN] 0890-9369
  • [Journal-full-title] Genes & development
  • [ISO-abbreviation] Genes Dev.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R56 CA092433; United States / NCI NIH HHS / CA / T32 CA 09140-31-35; United States / NCI NIH HHS / CA / R56 CA092433-06A1; United States / NCI NIH HHS / CA / R01 CA092433; United States / NCI NIH HHS / CA / T32 CA009140; None / None / / R01 CA092433-06A2; United States / NCI NIH HHS / CA / CA119130-01; United States / NCI NIH HHS / CA / R01 CA119130; United States / NCI NIH HHS / CA / P01 CA119070-01A19001; United States / NCI NIH HHS / CA / CA119070-01A19001; None / None / / R56 CA092433-06A1; United States / NCI NIH HHS / CA / R01 CA092433-06A2; United States / NCI NIH HHS / CA / R01 CA119130-01; United States / NCI NIH HHS / CA / P01 CA119070
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / NOTCH1 protein, human; 0 / Notch1 protein, mouse; 0 / Proto-Oncogene Proteins c-myc; 0 / Receptor, Notch1
  • [Other-IDs] NLM/ PMC1536060
  •  go-up   go-down


Advertisement
4. Fløisand Y, Brinch L, Dybedal I, Gedde-Dahl T, Heldal D, Holme PA, Egeland T, Tjønnfjord GE: [Allogeneic stem cell transplantation in adults with acute lymphoblastic leukaemia]. Tidsskr Nor Laegeforen; 2008 Nov 20;128(22):2563-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Allogeneic stem cell transplantation in adults with acute lymphoblastic leukaemia].
  • BACKGROUND: The success rate for chemotherapy of adults with acute lymphoblastic leukaemia in Norway compares favourably with that in international reports, but improvements are still needed.
  • MATERIAL AND METHODS: Allogen stem cell transplantation was performed in 61 high-risk patients (38 men and 23 women) with acute lymphoblastic leukaemia at Rikshospitalet between 1985 and 2005.
  • 19 patients were transplanted in first remission and 42 at a later stage of the disease.
  • INTERPRETATION: Our results are in line with international reports on the results of allogen stem cell transplantation in high-risk acute lymphoblastic leukaemia.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy
  • [MeSH-minor] Adolescent. Adult. Disease-Free Survival. Female. Graft vs Host Disease / diagnosis. Graft vs Host Disease / prevention & control. Humans. Male. Middle Aged. Remission Induction. Risk Factors. Survival Analysis. Transplantation Conditioning. Transplantation, Homologous. Treatment Outcome

  • Genetic Alliance. consumer health - Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19023351.001).
  • [ISSN] 0807-7096
  • [Journal-full-title] Tidsskrift for den Norske lægeforening : tidsskrift for praktisk medicin, ny række
  • [ISO-abbreviation] Tidsskr. Nor. Laegeforen.
  • [Language] nor
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Norway
  •  go-up   go-down


5. Sudhakar N, Nancy NK, Rajalekshmy KR, Rajkumar T: Diversity of T-cell receptor gene rearrangements in South Indian patients with common acute lymphoblastic leukemia. Iran J Immunol; 2009 Sep;6(3):141-6
Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diversity of T-cell receptor gene rearrangements in South Indian patients with common acute lymphoblastic leukemia.
  • BACKGROUND: Precursor B-Acute Lymphoblastic Leukemia (precursor B-ALL) occurs due to the uncontrolled proliferation of B-lymphoid precursors arrested at a particular stage of B-cell development.
  • Precursor-B-ALL is classified mainly into pro-B-ALL, common-ALL and pre-B-ALL.
  • The Common Acute Lymphoblastic Antigen CD10 is the marker for common-ALL.
  • [MeSH-major] Gene Rearrangement, delta-Chain T-Cell Antigen Receptor. Gene Rearrangement, gamma-Chain T-Cell Antigen Receptor. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Receptors, Antigen, T-Cell, gamma-delta / genetics
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Female. Genetic Variation. Humans. India. Male. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19801787.001).
  • [ISSN] 1735-1383
  • [Journal-full-title] Iranian journal of immunology : IJI
  • [ISO-abbreviation] Iran J Immunol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Iran
  • [Chemical-registry-number] 0 / Receptors, Antigen, T-Cell, gamma-delta
  •  go-up   go-down


6. Pan Y, Li GD, Liu WP, Zhang WY, Tang Y, Li FY: [Lymphoblastic lymphoma and acute lymphoblastic leukemia: a clinicopathologic, immunophenotypic and prognostic study in 153 Chinese patients]. Zhonghua Bing Li Xue Za Zhi; 2009 Dec;38(12):810-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Lymphoblastic lymphoma and acute lymphoblastic leukemia: a clinicopathologic, immunophenotypic and prognostic study in 153 Chinese patients].
  • OBJECTIVE: To study the clinicopathologic features, immunohistochemical findings and prognosis of precursor lymphoblastic lymphoma/acute lymphoblastic leukemia (LBL/ALL).
  • The pathologic findings were correlated with Ann Arbor tumor stage, Ki-67 index, other clinical parameters (including mediastinum/bone marrow involvement, hepato-splenomegaly, age and gender of the patients) and the survival data.
  • The cases were categorized into three groups according to the immunohistochemical findings, as follows: precursor T-cell, precursor B-cell and undefined.
  • Ninety-one cases (85.8%) were in stage III or IV at diagnosis.
  • Patients older than 25 years and those presented in stage III or IV suggested a poor prognosis (P = 0.049 and 0.001, respectively).
  • Twenty-one patients (72.4%) were in stage III or IV at diagnosis.
  • CONCLUSIONS: Both TdT and CD99 are useful markers for the diagnosis of precursor lymphoblastic malignancy.
  • The prognostic criteria include age of older than 25 years and a classification of stage III or IV disease.
  • [MeSH-major] Antigens, CD / metabolism. Cell Adhesion Molecules / metabolism. DNA Nucleotidylexotransferase / metabolism. Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology. Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / pathology
  • [MeSH-minor] Adolescent. Adult. Age Factors. Aged. Bone Marrow / pathology. Child. Child, Preschool. Female. Humans. Immunophenotyping. Male. Middle Aged. Neoplasm Staging. Prognosis. Retrospective Studies. Survival Rate. Young Adult


7. Specchia G, Pastore D, Carluccio P, Liso A, Mestice A, Rizzi R, Ciuffreda L, Pietrantuono G, Liso V: FLAG-IDA in the treatment of refractory/relapsed adult acute lymphoblastic leukemia. Ann Hematol; 2005 Nov;84(12):792-5
Hazardous Substances Data Bank. VIDARABINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] FLAG-IDA in the treatment of refractory/relapsed adult acute lymphoblastic leukemia.
  • Relapsed or refractory adult acute lymphoblastic leukemias (ALL) have poor prognosis.
  • Twenty three patients with relapsed/refractory adult ALL were treated with fludarabine, cytarabine, granulocyte colony-stimulating factor, and idarubicin (FLAG-IDA).
  • All nine patients who achieved CR received a second course with FLAG-IDA, and seven patients underwent allogeneic stem cell transplantation (four from a matched donor, one from a mismatched donor, and two from an unrelated donor), while two did not reach that stage due to early relapse from CR.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy. Stem Cell Transplantation
  • [MeSH-minor] Adult. Aged. Antibiotics, Antineoplastic / administration & dosage. Antibiotics, Antineoplastic / adverse effects. Cytarabine / administration & dosage. Cytarabine / adverse effects. Disease-Free Survival. Female. Granulocyte Colony-Stimulating Factor / administration & dosage. Granulocyte Colony-Stimulating Factor / adverse effects. Humans. Idarubicin / administration & dosage. Idarubicin / adverse effects. Leukocyte Count. Liver / injuries. Male. Middle Aged. Mucositis / etiology. Platelet Count. Recurrence. Remission Induction. Retrospective Studies. Salvage Therapy. Transplantation, Homologous. Treatment Outcome. Vidarabine / administration & dosage. Vidarabine / adverse effects. Vidarabine / analogs & derivatives

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. FLUDARABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16047203.001).
  • [ISSN] 0939-5555
  • [Journal-full-title] Annals of hematology
  • [ISO-abbreviation] Ann. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 04079A1RDZ / Cytarabine; 143011-72-7 / Granulocyte Colony-Stimulating Factor; FA2DM6879K / Vidarabine; P2K93U8740 / fludarabine; ZRP63D75JW / Idarubicin
  •  go-up   go-down


8. Parovichnikova EN, Savchenko VG, Verniuk MA, Vinogradova OA, Misiurin AV, Vorob'ev IA, Domracheva EV, Tikhonova LIu, Rukavitsyn OA, Rossiev VA, Kliasova GA, Turkina AG, Liubimova LS, Mendeleeva LP, Isaev VG: [Acute lymphoblastic leukemias with aberrations of BCR-ABL genes]. Ter Arkh; 2005;77(7):11-6
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Acute lymphoblastic leukemias with aberrations of BCR-ABL genes].
  • AIM: To develop an original therapeutic strategy in Ph-positive acute lymphoblastic leukemia (ALL).
  • During the first stage of the study (November 2001-July 2004), 18 primary ALL patients were recruited in HRC, from July 2004 to January 2005--16 patients in HRC, N.N.
  • [MeSH-major] Fusion Proteins, bcr-abl / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics
  • [MeSH-minor] Adolescent. Adult. Antineoplastic Agents / therapeutic use. Benzamides. Female. Follow-Up Studies. Humans. Imatinib Mesylate. In Situ Hybridization, Fluorescence. Male. Middle Aged. Piperazines / therapeutic use. Pyrimidines / therapeutic use. Remission Induction. Retrospective Studies. Reverse Transcriptase Polymerase Chain Reaction. Treatment Outcome

  • Hazardous Substances Data Bank. IMATINIB MESYLATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16116902.001).
  • [ISSN] 0040-3660
  • [Journal-full-title] Terapevticheskiĭ arkhiv
  • [ISO-abbreviation] Ter. Arkh.
  • [Language] rus
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzamides; 0 / Piperazines; 0 / Pyrimidines; 8A1O1M485B / Imatinib Mesylate; EC 2.7.10.2 / Fusion Proteins, bcr-abl
  •  go-up   go-down


9. Jabbour E, Koscielny S, Sebban C, Peslin N, Patte C, Gargi T, Biron P, Fermé C, Bourhis JH, Vantelon JM, Arnaud P, Ribrag V: High survival rate with the LMT-89 regimen in lymphoblastic lymphoma (LL), but not in T-cell acute lymphoblastic leukemia (T-ALL). Leukemia; 2006 May;20(5):814-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High survival rate with the LMT-89 regimen in lymphoblastic lymphoma (LL), but not in T-cell acute lymphoblastic leukemia (T-ALL).
  • The most appropriate treatment for lymphoblastic lymphomas (LL) remains uncertain.
  • Four patients had central nervous system involvement and 12 had bone marrow involvement and 24/27 (89%) had advanced Ann Arbor stage III-IV disease.
  • The Ann Arbor stage, age and serum lactate dehydrogenase level did not influence outcomes.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Leukemia-Lymphoma, Adult T-Cell / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy
  • [MeSH-minor] Adolescent. Adult. Bone Marrow / pathology. Disease Progression. Disease-Free Survival. Dose-Response Relationship, Drug. Female. Follow-Up Studies. Humans. Male. Middle Aged. Predictive Value of Tests. Prognosis. Remission Induction. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Lymphoblastic lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16511514.001).
  • [ISSN] 0887-6924
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article
  • [Publication-country] England
  •  go-up   go-down


10. Qin Y, Shi YK, He XH, Han XH, Zhou SY, Liu P, Yang JL, Yang S, Zhang CG, Dong M, Zhou LQ, Wang JW, Feng FY, Sun Y: [Comparison of the efficiency of CHOP-based regimen with or without high dose consolidation treatment combined with hematopoietic stem cell transplantation in 63 lymphoblastic lymphoma patients]. Zhonghua Zhong Liu Za Zhi; 2009 Jun;31(6):469-73
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Comparison of the efficiency of CHOP-based regimen with or without high dose consolidation treatment combined with hematopoietic stem cell transplantation in 63 lymphoblastic lymphoma patients].
  • OBJECTIVE: To retrospectively analyze and compare the treatment efficiency of CHOP-based regimens with or without high-dose consolidation treatment combined with hematopoietic stem cell transplantation (HDT-HSCT) in the patients with lymphoblastic lymphoma (LBL).
  • RESULTS: Of the 63 patients, 57 had a T-LBL and 6 B-LBL, with a median age of 20 years, 19 (30.2%) had a stage I-II diseases and 44 (69.8%) stage III-IV diseases, 61.9% presented with a mediastinal mass.
  • CONCLUSION: Short term treatment with a CHOP-based regimen is not sufficient for the patients with lymphoblastic lymphoma.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bone Marrow / pathology. Hematopoietic Stem Cell Transplantation. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Child, Preschool. Combined Modality Therapy. Cyclophosphamide / administration & dosage. Cyclophosphamide / therapeutic use. Disease-Free Survival. Dose-Response Relationship, Drug. Doxorubicin / administration & dosage. Doxorubicin / therapeutic use. Female. Follow-Up Studies. Humans. Male. Middle Aged. Prednisone / administration & dosage. Prednisone / therapeutic use. Remission Induction. Retrospective Studies. Survival Rate. Vincristine / administration & dosage. Vincristine / therapeutic use. Young Adult

  • Genetic Alliance. consumer health - Lymphoblastic lymphoma.
  • Genetic Alliance. consumer health - Transplantation.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19950562.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] Comparative Study; English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


11. Gökbuget N, Hoelzer D: Novel antibody-based therapy for acute lymphoblastic leukaemia. Best Pract Res Clin Haematol; 2006;19(4):701-13
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Novel antibody-based therapy for acute lymphoblastic leukaemia.
  • In recent decades rapid improvements in the results of treatment of adult acute lymphoblastic leukaemia (ALL) have been achieved.
  • However, results in adult patients are still considerably inferior to those in paediatric ALL, and a barrier to further intensification of chemotherapy appears to have been reached regarding toxicity.
  • In ALL, rituximab is combined with chemotherapy mainly in mature B-ALL and Burkitt's lymphoma, and interim results are very promising.
  • Recently studies with rituximab have also been initiated in B-precursor ALL.
  • Details of these regimens - required level of antigen expression, timing, schedule, dosage and stage of disease - remain to be defined.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antigens, CD / drug effects. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16997178.001).
  • [ISSN] 1521-6926
  • [Journal-full-title] Best practice & research. Clinical haematology
  • [ISO-abbreviation] Best Pract Res Clin Haematol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antigens, CD
  • [Number-of-references] 54
  •  go-up   go-down


12. Lee RV, Braylan RC, Rimsza LM: CD58 expression decreases as nonmalignant B cells mature in bone marrow and is frequently overexpressed in adult and pediatric precursor B-cell acute lymphoblastic leukemia. Am J Clin Pathol; 2005 Jan;123(1):119-24
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CD58 expression decreases as nonmalignant B cells mature in bone marrow and is frequently overexpressed in adult and pediatric precursor B-cell acute lymphoblastic leukemia.
  • We used flow cytometry to determine the CD58 expression on nonmalignant B cells at different stages of maturation in the bone marrow and compared it with that of blasts in adult and pediatric precursor B-cell acute lymphoblastic leukemia (B-ALL).
  • The mean fluorescence intensity (MFI) of CD58 expression decreased significantly as nonmalignant B cells differentiated in the bone marrow from an early to a mature stage.
  • Few nonneoplastic B cells at a mid or mature stage of development expressed CD58 MFI values comparable to those seen in leukemic cases.
  • Early-stage nonneoplastic B-cell precursors expressed relatively higher CD58 levels, which frequently overlapped with the variable level of CD58 expression observed among leukemic blasts.
  • As a group, however, the malignant precursor B-ALL cells showed significantly higher expression of CD58 than nonmalignant B-cell populations at any maturational stage.
  • These findings support the potential usefulness of CD58 expression in the diagnosis and monitoring of precursor B-ALL, but only when blasts express high levels of CD58.
  • [MeSH-major] Antigens, CD58 / analysis. B-Lymphocytes / physiology. Bone Marrow Cells / physiology. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / immunology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / immunology
  • [MeSH-minor] Adolescent. Adult. Aged. Antigens, CD34 / analysis. Child. Child, Preschool. Humans. Middle Aged

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15762287.001).
  • [ISSN] 0002-9173
  • [Journal-full-title] American journal of clinical pathology
  • [ISO-abbreviation] Am. J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD34; 0 / Antigens, CD58
  •  go-up   go-down


13. Jin FY, Zou DH, Wang GR, Xu Y, Feng SZ, Zhao YZ, Han MZ, Yan WW, Qiu LG: [Comparison of the effectiveness of chemotherapy and autologous hematopoietic stem cell transplantation as postremission treatment for adult acute lymphoblastic leukemia patients]. Zhonghua Xue Ye Xue Za Zhi; 2005 Nov;26(11):645-8
Genetic Alliance. consumer health - Transplantation.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Comparison of the effectiveness of chemotherapy and autologous hematopoietic stem cell transplantation as postremission treatment for adult acute lymphoblastic leukemia patients].
  • OBJECTIVE: To evaluate the effectiveness of chemotherapy (CT) and autologous hematopoietic stem cell transplantation (ASCT) as post-remission treatment for adult acute lymphoblastic leukemia (AL) patients.
  • METHODS: Seventy-four ALL patients achieved first complete remission (CR(1)) with induction therapy, and then received early-stage sequential intensive consolidation chemotherapy.
  • CONCLUSIONS: Early sequential intensive consolidation chemotherapy followed by auto-HSCT could significantly reduce late relapse rate for adult ALL patients, and those received ex vivo purged autografts and immunotherapy and (or) maintenance therapy after ASCT have lower late relapse rate and superior survival.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hematopoietic Stem Cell Transplantation. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / surgery
  • [MeSH-minor] Adolescent. Adult. Female. Follow-Up Studies. Humans. Male. Retrospective Studies. Transplantation, Autologous. Treatment Outcome

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16620547.001).
  • [ISSN] 0253-2727
  • [Journal-full-title] Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
  • [ISO-abbreviation] Zhonghua Xue Ye Xue Za Zhi
  • [Language] chi
  • [Publication-type] Comparative Study; English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  •  go-up   go-down


14. Zhang W, Fu R, Liu WH, Cheng YQ, Song WX, DU LJ, Ruan EB, Zhang LT, Wang XM, Liang Y, Wang GJ, Qu W, Song J, Zhang RL, Guan J, Li LJ, Zou P, Shao ZH: [Prognosis and related factors of acute lymphoblastic leukemia]. Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2007 Oct;15(5):1102-6
Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Prognosis and related factors of acute lymphoblastic leukemia].
  • In order to analyze the prognosis and related factors of acute lymphoblastic leukemia (ALL), 53 newly diagnosed ALL patients were enrolled in this study.
  • The therapeutic efficacy and prognosis of 53 cases of ALL were analyzed, the remission, relapse, overall survival and event-free survival were studied, and relation between different factors and prognosis of ALL were investigated by comparison of cases in same stage.
  • It is concluded that there is higher relapse rate, poor prognosis in adult ALL in comparison with children.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17956700.001).
  • [ISSN] 1009-2137
  • [Journal-full-title] Zhongguo shi yan xue ye xue za zhi
  • [ISO-abbreviation] Zhongguo Shi Yan Xue Ye Xue Za Zhi
  • [Language] CHI
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


15. Bariakh EA, Kravchenko SK, Kremenetskaia AM, Zvonkov EE, Obukhova TN, Magomedova AU, Vorob'ev AI: [Clinical and epidemiological features of Burkitt's lymphoma]. Ter Arkh; 2009;81(7):47-53
Genetic Alliance. consumer health - Burkitt's Lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical and epidemiological features of Burkitt's lymphoma].
  • AIM: To characterize clinical and epidemiological features of adult Berkitt's lymphoma (BL).
  • RESULTS: Stage I BL (by S.B.
  • Murphy) was diagnosed in 5 patients, stage II--in 9, stage III--in 25, IV--in 14 patients, B-cell acute lymphoblastic leukemia (ALL) (L3)--in 19 patients.
  • [MeSH-major] Burkitt Lymphoma / diagnosis. Burkitt Lymphoma / epidemiology
  • [MeSH-minor] Adolescent. Adult. Age Factors. Aged. Female. Humans. L-Lactate Dehydrogenase / metabolism. Male. Middle Aged. Neoplasm Staging. Sex Factors. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19708573.001).
  • [ISSN] 0040-3660
  • [Journal-full-title] Terapevticheskiĭ arkhiv
  • [ISO-abbreviation] Ter. Arkh.
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] EC 1.1.1.27 / L-Lactate Dehydrogenase
  •  go-up   go-down


16. Kagu MB, Ahmed SG, Bukar AA: Pre-treatment tumour lysis syndrome and acute renal failure in adult Nigerians with Burkitt's lymphoma: report of three cases and literature review. Afr J Med Med Sci; 2005 Dec;34(4):399-402
Genetic Alliance. consumer health - Burkitt's Lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pre-treatment tumour lysis syndrome and acute renal failure in adult Nigerians with Burkitt's lymphoma: report of three cases and literature review.
  • Pre-treatment tumour lysis syndrome (pre-TTLS) is not an unusual clinical entity in high-grade lymphomas and lymphoblastic leukaemias.
  • The overall incidence and frequency is unknown and to the best of our knowledge none has been published in Nigeria involving adult females with advanced stage Burkitt's lymphoma (ASBL).
  • This paper stresses the importance of aggressive supportive management and slow introduction of cytotoxic chemotherapy in patients with a stage C and/or stage D Burkitt's lymphoma presenting with pre-TTLS.
  • [MeSH-major] Burkitt Lymphoma / complications. Renal Insufficiency / etiology. Tumor Lysis Syndrome / etiology
  • [MeSH-minor] Acute Disease. Adolescent. Adult. Fatal Outcome. Female. Humans. Nigeria. Risk Assessment. Risk Factors. Time Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16752673.001).
  • [ISSN] 0309-3913
  • [Journal-full-title] African journal of medicine and medical sciences
  • [ISO-abbreviation] Afr J Med Med Sci
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Nigeria
  •  go-up   go-down


17. Baleydier F, Decouvelaere AV, Bergeron J, Gaulard P, Canioni D, Bertrand Y, Lepretre S, Petit B, Dombret H, Beldjord K, Molina T, Asnafi V, Macintyre E: T cell receptor genotyping and HOXA/TLX1 expression define three T lymphoblastic lymphoma subsets which might affect clinical outcome. Clin Cancer Res; 2008 Feb 1;14(3):692-700
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] T cell receptor genotyping and HOXA/TLX1 expression define three T lymphoblastic lymphoma subsets which might affect clinical outcome.
  • PURPOSE: T lymphoblastic lymphomas (T-LBL) are rare disorders of immature T cells which predominantly involve the mediastinum.
  • EXPERIMENTAL DESIGN: We undertook a retrospective study of 41 cytoplasmic CD3+ T-LBL (nine cases aged <16 years) by assessing stage of maturation arrest based on T cell receptor (TCR) immunogenotyping, immunohistochemistry, and quantification of the oncogenes thought to be important in immature T cell malignancies.
  • CONCLUSION: Application of this molecular classification will allow the prospective evaluation of prognostic effects within pediatric and adult protocols.
  • [MeSH-major] Homeodomain Proteins / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Proto-Oncogene Proteins / genetics. Receptors, Antigen, T-Cell / genetics
  • [MeSH-minor] Adolescent. Adult. Aged. Biopsy. Child. Child, Preschool. DNA, Neoplasm / genetics. Female. Genotype. Humans. Lymph Nodes / pathology. Male. Middle Aged. Pleural Effusion / genetics. Polymerase Chain Reaction. Receptor, Notch1 / genetics. Retrospective Studies

  • Genetic Alliance. consumer health - Lymphoblastic lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18245528.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Neoplasm; 0 / Homeodomain Proteins; 0 / Proto-Oncogene Proteins; 0 / Receptor, Notch1; 0 / Receptors, Antigen, T-Cell; 143275-75-6 / TLX1 protein, human; 157907-48-7 / HoxA protein
  •  go-up   go-down


18. Jmili NB, Souguir S, Yacoub S, Khelif A, Kortas M: [Study of antigenic profile of blasts in acute lymphoblastic leukemia: flow cytometric analysis of 152 cases]. Ann Biol Clin (Paris); 2009 Sep-Oct;67(5):543-51
Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Study of antigenic profile of blasts in acute lymphoblastic leukemia: flow cytometric analysis of 152 cases].
  • The aim of this study was to characterize the antigenic profile of blasts in acute lymphoblastic leukaemia (ALL) and to determine possible phenotypic aberrancies in a series of 152 patients with acute leukaemia diagnosed non myeloid leukaemia in cytology.
  • Based on criteria of EGIL (European Group of Immunological Leukaemia), cases were classified as: acute lymphoblastic leukaemia (ALL, 52,6%); 75% cases of ALL belong to lymphoid B lineage.
  • Flow cytometry has wide field of applications to characterize blast cells from patients with acute leukaemia: to establish diagnosis of lineage responsible in proliferation, to determine the stage of maturation, to predict prognosis for a better adaptation of adequate treatment, to follow evolution of disease after chemotherapy and to study minimal residual disease.
  • [MeSH-major] Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Child, Preschool. Female. Flow Cytometry. Humans. Immunophenotyping. Infant. Male. Middle Aged. Neprilysin / analysis. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19789126.001).
  • [ISSN] 0003-3898
  • [Journal-full-title] Annales de biologie clinique
  • [ISO-abbreviation] Ann. Biol. Clin. (Paris)
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] EC 3.4.24.11 / Neprilysin
  •  go-up   go-down


19. Mansur MB, Emerenciano M, Brewer L, Sant'Ana M, Mendonça N, Thuler LC, Koifman S, Pombo-de-Oliveira MS: SIL-TAL1 fusion gene negative impact in T-cell acute lymphoblastic leukemia outcome. Leuk Lymphoma; 2009 Aug;50(8):1318-25
Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] SIL-TAL1 fusion gene negative impact in T-cell acute lymphoblastic leukemia outcome.
  • SIL-TAL1 fusion gene and the ectopic expression of HOX11L2 are common molecular abnormalities in T-cell acute lymphoblastic leukemia (T-ALL).
  • The most frequent maturation stage was T-IV (40.1%), and 30.7% of cases were CD10(+).
  • [MeSH-major] Homeodomain Proteins / analysis. Oncogene Proteins, Fusion / blood. Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / genetics
  • [MeSH-minor] Adolescent. Age Factors. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Brazil / epidemiology. Child. Child, Preschool. Female. Follow-Up Studies. Humans. Immunophenotyping. Infant. Infant, Newborn. Kaplan-Meier Estimate. Male. Reverse Transcriptase Polymerase Chain Reaction. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19562638.001).
  • [ISSN] 1029-2403
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Homeodomain Proteins; 0 / Oncogene Proteins, Fusion; 0 / SIL-TAL1 fusion protein, human; 0 / TLX3 protein, human
  •  go-up   go-down


20. Kaste SC, Thomas NA, Rai SN, Cheon K, McCammon E, Chesney R, Jones D, Pui CH, Hudson MM: Asymptomatic kidney stones in long-term survivors of childhood acute lymphoblastic leukemia. Leukemia; 2009 Jan;23(1):104-8
Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Asymptomatic kidney stones in long-term survivors of childhood acute lymphoblastic leukemia.
  • We hypothesized an association between renal calculi and bone mineral density (BMD) deficits, shown in adults, exists in survivors of childhood acute lymphoblastic leukemia (ALL).
  • Thus, we analyzed the associations between quantitative computed tomography (QCT)-determined renal calcifications and clinical parameters (gender, race, age at diagnosis and age at the time of QCT), BMD, treatment exposures and Tanner stage.

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia, Childhood.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Urology. 2002 Jun;59(6):865-9; discussion 869 [12031370.001]
  • [Cites] Kidney Int. 2003 Feb;63(2):662-9 [12631132.001]
  • [Cites] Leukemia. 2003 Mar;17(3):541-6 [12646942.001]
  • [Cites] J Nephrol. 2003 Mar-Apr;16(2):260-6 [12768074.001]
  • [Cites] Nephron Clin Pract. 2003;94(4):c89-93 [12972718.001]
  • [Cites] J Clin Endocrinol Metab. 1982 Aug;55(2):369-73 [6896338.001]
  • [Cites] N Engl J Med. 1983 Apr 28;308(17):995-9 [6835318.001]
  • [Cites] Pediatr Rev. 1989 Jul;11(1):21-30 [2664747.001]
  • [Cites] Am J Public Health. 1991 May;81(5):587-91 [2014858.001]
  • [Cites] J Bone Miner Res. 1992 Dec;7(12):1383-8 [1481724.001]
  • [Cites] N Engl J Med. 1993 Mar 25;328(12):833-8 [8441427.001]
  • [Cites] J Urol. 1993 Aug;150(2 Pt 1):310-2 [8326549.001]
  • [Cites] Curr Opin Pediatr. 1993 Apr;5(2):186-90 [8374638.001]
  • [Cites] Ann Nutr Metab. 1997;41(5):269-82 [9429689.001]
  • [Cites] Am J Epidemiol. 1998 May 15;147(10):914-20 [9596469.001]
  • [Cites] J Pediatr Hematol Oncol. 1998 May-Jun;20(3):241-5 [9628436.001]
  • [Cites] Scand J Urol Nephrol. 1998 May;32(3):177-80 [9689695.001]
  • [Cites] Am J Kidney Dis. 1999 Jan;33(1):xlvi-xlviii [9915260.001]
  • [Cites] Contrib Nephrol. 2005;147:132-48 [15604613.001]
  • [Cites] JAMA. 2005 Jan 26;293(4):455-62 [15671430.001]
  • [Cites] Int J Urol. 2005 Apr;12(4):335-9 [15948718.001]
  • [Cites] Pediatr Nephrol. 2005 Nov;20(11):1587-92 [16133066.001]
  • [Cites] Pediatr Blood Cancer. 2006 Jan;46(1):77-87 [16106430.001]
  • [Cites] Urology. 2006 Apr;67(4):812-6 [16566973.001]
  • [Cites] J Child Health Care. 2006 Dec;10(4):337-50 [17101625.001]
  • [Cites] Pediatr Nephrol. 2007 Jan;22(1):132-5 [17039332.001]
  • [Cites] Am J Kidney Dis. 2006 Dec;48(6):905-15 [17162145.001]
  • [Cites] J Urol. 2007 Jun;177(6):2300-5 [17509344.001]
  • [Cites] Clin Nephrol. 2000 Aug;54(2):85-93 [10968683.001]
  • [Cites] Am J Surg. 2000 Nov;180(5):357-61 [11137687.001]
  • [Cites] Leukemia. 2001 May;15(5):728-34 [11368432.001]
  • [Cites] J Bone Miner Res. 2001 Oct;16(10):1893-8 [11585355.001]
  • [Cites] N Engl J Med. 2002 Jan 10;346(2):77-84 [11784873.001]
  • (PMID = 18830261.001).
  • [ISSN] 1476-5551
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P30 CA-21765; United States / NCI NIH HHS / CA / P30 CA021765; United States / NCI NIH HHS / CA / P01 CA-20180; United States / NCI NIH HHS / CA / CA020180-209003; None / None / / P30 CA021765-30; United States / NCI NIH HHS / CA / P01 CA020180; United States / NCI NIH HHS / CA / P01 CA020180-209003; United States / NCI NIH HHS / CA / P30 CA021765-30
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Other-IDs] NLM/ NIHMS89657; NLM/ PMC2645541
  •  go-up   go-down


21. Martens C, Hodgson DC, Wells WA, Sun A, Bezjak A, Pintilie M, Crump M, Gospodarowicz MK, Tsang R: Outcome of hyperfractionated radiotherapy in chemotherapy-resistant non-Hodgkin's lymphoma. Int J Radiat Oncol Biol Phys; 2006 Mar 15;64(4):1183-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcome of hyperfractionated radiotherapy in chemotherapy-resistant non-Hodgkin's lymphoma.
  • PURPOSE: Patients with chemotherapy-resistant lymphoma have rapidly progressive disease and a poor prognosis.
  • The initial diagnosis was Stage I-II in 56% and Stage III-IV in 44%.
  • The histologic features at diagnosis were follicular in 11 (Grade 1 in 4, Grade 2 in 3, and Grade 3 in 4), diffuse large B-cell in 14, peripheral T-cell lymphoma in 2, Burkitt-like in 1, mantle cell in 2, natural killer cell in 2, plasmacytoma/lymphoma in 1, and T-cell lymphoblastic in 1.
  • [MeSH-major] Lymphoma, Non-Hodgkin / radiotherapy
  • [MeSH-minor] Adult. Aged. Disease Progression. Dose Fractionation. Drug Resistance, Neoplasm. Female. Humans. Male. Middle Aged. Remission Induction. Survivors. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16376490.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


22. Terwey TH, Hemmati PG, Martus P, Dietz E, Vuong LG, Massenkeil G, Dörken B, Arnold R: A modified EBMT risk score and the hematopoietic cell transplantation-specific comorbidity index for pre-transplant risk assessment in adult acute lymphoblastic leukemia. Haematologica; 2010 May;95(5):810-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A modified EBMT risk score and the hematopoietic cell transplantation-specific comorbidity index for pre-transplant risk assessment in adult acute lymphoblastic leukemia.
  • BACKGROUND: Disease stage is the most important prognostic parameter in allogeneic hematopoietic cell transplantation (HCT) for acute lymphoblastic leukemia, but other factors such as donor/host histocompatibility and gender combination, recipient age, performance status and comorbidities need to be considered.
  • Several scoring systems are available to predict outcome in HCT recipients; however, their prognostic relevance in acute lymphoblastic leukemia is not well defined.
  • DESIGN AND METHODS: In the present study we evaluated a modified EBMT risk score (mEBMT) and the HCT-specific comorbidity index (HCT-CI) in 151 adult acute lymphoblastic leukemia patients who received allogeneic HCT from 1995 until 2007 at our center.
  • Disease stage was the predominant prognostic factor in this score.
  • However, KPS was associated with disease stage and significance was lost in multivariate analysis.
  • CONCLUSIONS: The mEBMT was prognostic in our patient cohort with predominant influence of disease stage, whereas a trend but no significant prognostic value was observed for the HCT-CI.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation / standards. Karnofsky Performance Status / standards. Precursor Cell Lymphoblastic Leukemia-Lymphoma / surgery. Preoperative Care / standards. Transplantation Conditioning / standards
  • [MeSH-minor] Adolescent. Adult. Aged. Cohort Studies. Comorbidity. Female. Follow-Up Studies. Humans. Male. Middle Aged. Research Design / standards. Retrospective Studies. Risk Assessment. Risk Factors. Young Adult

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Biol Blood Marrow Transplant. 2003 Jul;9(7):472-81 [12869961.001]
  • [Cites] Blood. 2001 Mar 15;97(6):1572-7 [11238093.001]
  • [Cites] Bone Marrow Transplant. 1996 Jan;17(1):13-8 [8673048.001]
  • [Cites] Lancet. 1998 Oct 3;352(9134):1087-92 [9798583.001]
  • [Cites] Blood. 2005 Oct 15;106(8):2912-9 [15994282.001]
  • [Cites] Ann Intern Med. 2006 Mar 21;144(6):407-14 [16549853.001]
  • [Cites] Biol Blood Marrow Transplant. 2006 Sep;12(9):954-64 [16920562.001]
  • [Cites] J Clin Oncol. 2006 Sep 1;24(25):4150-7 [16896000.001]
  • [Cites] Br J Haematol. 2006 Oct;135(2):201-9 [16939494.001]
  • [Cites] Biol Blood Marrow Transplant. 2007 Aug;13(8):932-41 [17640597.001]
  • [Cites] Bone Marrow Transplant. 2007 Aug;40(4):381-7 [17563735.001]
  • [Cites] J Clin Oncol. 2007 Sep 20;25(27):4246-54 [17724349.001]
  • [Cites] Biol Blood Marrow Transplant. 2007 Dec;13(12):1499-507 [18022580.001]
  • [Cites] Blood. 2007 Dec 15;110(13):4606-13 [17873123.001]
  • [Cites] Blood. 2008 Jan 1;111(1):446-52 [17916744.001]
  • [Cites] Biol Blood Marrow Transplant. 2008 Jan;14(1):28-35 [18158958.001]
  • [Cites] Bone Marrow Transplant. 2008 Apr;41(8):721-7 [18176613.001]
  • [Cites] Cancer. 2008 May 1;112(9):1992-2001 [18311781.001]
  • [Cites] Bone Marrow Transplant. 2008 May;41(9):805-12 [18195682.001]
  • [Cites] Biol Blood Marrow Transplant. 2008 Sep;14(9):985-92 [18721761.001]
  • [Cites] Clin Cancer Res. 2008 Sep 1;14(17):5585-93 [18765552.001]
  • [Cites] J Clin Oncol. 2008 Oct 20;26(30):4912-20 [18794548.001]
  • [Cites] Biol Blood Marrow Transplant. 2008 Nov;14(11):1217-25 [18940675.001]
  • [Cites] Br J Haematol. 2008 Nov;143(3):395-403 [18759762.001]
  • [Cites] Leukemia. 2008 Nov;22(11):2062-9 [18685612.001]
  • [Cites] Eur J Clin Invest. 2008 Dec;38(12):945-52 [19021720.001]
  • [Cites] Biol Blood Marrow Transplant. 2009 Jan;15(1 Suppl):149-53 [19147097.001]
  • [Cites] Biol Blood Marrow Transplant. 2009 Feb;15(2):223-30 [19167682.001]
  • [Cites] Bone Marrow Transplant. 2009 Jan;43(2):133-9 [18762762.001]
  • [Cites] Blood. 2009 Mar 26;113(13):2902-5 [19179301.001]
  • [Cites] Leukemia. 2009 Jun;23(6):1131-8 [19194465.001]
  • [Cites] Curr Hematol Malig Rep. 2009 Jul;4(3):139-47 [20425427.001]
  • [Cites] Hematol Oncol Clin North Am. 2000 Dec;14(6):1307-25, ix [11147225.001]
  • [Cites] Leukemia. 2003 Aug;17(8):1596-9 [12886248.001]
  • (PMID = 20007143.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Italy
  • [Other-IDs] NLM/ PMC2864388
  •  go-up   go-down


23. Chow EJ, Pihoker C, Hunt K, Wilkinson K, Friedman DL: Obesity and hypertension among children after treatment for acute lymphoblastic leukemia. Cancer; 2007 Nov 15;110(10):2313-20
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Obesity and hypertension among children after treatment for acute lymphoblastic leukemia.
  • BACKGROUND: The purpose was to determine the prevalence and treatment-related risk factors for obesity and hypertension among childhood acute lymphoblastic leukemia (ALL) survivors treated with contemporary therapy.
  • At the end of therapy, 17.0% of survivors were overweight (BMI of 25-29, or 85-94% for age), 21.2% were obese (BMI >or=30, or >or=95% for age), and 15.3% had BP meeting stage 1+ hypertension thresholds (systolic or diastolic BP >or=140/90 mm Hg, or 95% for age and height plus 5 mm Hg).
  • In multivariate analysis, the highest level of corticosteroid exposure was associated with both obesity (odds ratio [OR] 6.0; 95% confidence interval [95% CI], 1.2-28.5) as well as stage 1+ hypertension (OR 2.4; 95% CI, 1.2-5.1) compared with the lowest level.
  • [MeSH-major] Hypertension / complications. Obesity / complications. Precursor Cell Lymphoblastic Leukemia-Lymphoma / complications
  • [MeSH-minor] Adolescent. Adult. Antineoplastic Agents / therapeutic use. Child. Child, Preschool. Humans. Longitudinal Studies. Prevalence. Risk Factors


24. Bousquet M, Broccardo C, Quelen C, Meggetto F, Kuhlein E, Delsol G, Dastugue N, Brousset P: A novel PAX5-ELN fusion protein identified in B-cell acute lymphoblastic leukemia acts as a dominant negative on wild-type PAX5. Blood; 2007 Apr 15;109(8):3417-23
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A novel PAX5-ELN fusion protein identified in B-cell acute lymphoblastic leukemia acts as a dominant negative on wild-type PAX5.
  • We report a novel t(7;9)(q11;p13) translocation in 2 patients with B-cell acute lymphoblastic leukemia (B-ALL).
  • After cloning the full-length cDNA of the chimeric gene, confocal microscopy of transfected NIH3T3 cells and Burkitt lymphoma cells (DG75) demonstrated that PAX5-ELN was localized in the nucleus.
  • Since PAX5 is essential for B-cell differentiation, this translocation may account for the blockage of leukemic cells at the pre-B-cell stage.
  • [MeSH-major] B-Cell-Specific Activator Protein / genetics. Burkitt Lymphoma / genetics. Chromosomes, Human, Pair 7 / genetics. Chromosomes, Human, Pair 9 / genetics. Elastin / genetics. Genes, Dominant. Oncogene Proteins, Fusion / genetics. Translocation, Genetic
  • [MeSH-minor] Adolescent. Adult. Animals. Antigens, CD19 / biosynthesis. Antigens, CD19 / genetics. Cell Differentiation / genetics. Cell Nucleus / genetics. Cell Nucleus / metabolism. Cell Nucleus / pathology. HeLa Cells. Humans. Male. Mice. NIH 3T3 Cells. Promoter Regions, Genetic / genetics. Transcription, Genetic / genetics

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17179230.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD19; 0 / B-Cell-Specific Activator Protein; 0 / Oncogene Proteins, Fusion; 0 / PAX5 protein, human; 9007-58-3 / Elastin
  •  go-up   go-down


25. Tylavsky FA, Smith K, Surprise H, Garland S, Yan X, McCammon E, Hudson MM, Pui CH, Kaste SC: Nutritional intake of long-term survivors of childhood acute lymphoblastic leukemia: evidence for bone health interventional opportunities. Pediatr Blood Cancer; 2010 Dec 15;55(7):1362-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nutritional intake of long-term survivors of childhood acute lymphoblastic leukemia: evidence for bone health interventional opportunities.
  • BACKGROUND: Survivors of childhood acute lymphoblastic leukemia (ALL) are vulnerable to exaggeration of the aging process including decreased bone mineral density (BMD).
  • Body mass index was compared to the general US population, adjusted for age, gender, Tanner stage and race.

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia, Childhood.
  • MedlinePlus Health Information. consumer health - Bone Density.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Acta Paediatr Suppl. 1999 Dec;88(433):1-4 [10626537.001]
  • [Cites] J Bone Miner Res. 1994 Apr;9(4):459-63 [8030433.001]
  • [Cites] J Nutr. 2006 Jun;136(6):1453-6 [16702302.001]
  • [Cites] J Pediatr. 2006 Oct;149(4):518-25 [17011325.001]
  • [Cites] Leukemia. 2001 May;15(5):728-34 [11368432.001]
  • [Cites] J Bone Miner Res. 2002 Jul;17(7):1230-6 [12096836.001]
  • [Cites] J Nutr. 2002 Nov;132(11 Suppl):3494S-3503S [12421876.001]
  • [Cites] J Gerontol A Biol Sci Med Sci. 2003 Jan;58(1):82-91 [12560417.001]
  • [Cites] J Clin Oncol. 2003 Apr 1;21(7):1359-65 [12663727.001]
  • [Cites] Bone. 2003 Apr;32(4):372-80 [12689680.001]
  • [Cites] Prev Med. 2003 May;36(5):615-23 [12689807.001]
  • [Cites] Adv Data. 2003 Apr 17;(334):1-4 [12743879.001]
  • [Cites] JAMA. 2003 Sep 24;290(12):1583-92 [14506117.001]
  • [Cites] J Nutr. 2003 Nov;133(11):3592-7 [14608079.001]
  • [Cites] J Clin Endocrinol Metab. 2004 Apr;89(4):1858-63 [15070956.001]
  • [Cites] J Bone Miner Res. 2004 Jul;19(7):1084-91 [15176990.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2006 Oct;15(10):1969-76 [17035407.001]
  • [Cites] Br J Nutr. 2007 Apr;97(4):661-6 [17349078.001]
  • [Cites] MMWR Morb Mortal Wkly Rep. 2007 Mar 16;56(10):213-7 [17363889.001]
  • [Cites] J Clin Oncol. 2007 Apr 1;25(10):1183-9 [17401007.001]
  • [Cites] Cancer. 2007 Nov 15;110(10):2313-20 [17896787.001]
  • [Cites] Bone. 2007 Dec;41(6):987-94 [17936100.001]
  • [Cites] Calcif Tissue Int. 2008 Jan;82(1):1-11 [18175033.001]
  • [Cites] Pediatr Blood Cancer. 2008 Jul;51(1):118-22 [18338394.001]
  • [Cites] JAMA. 2008 May 28;299(20):2401-5 [18505949.001]
  • [Cites] Int J Vitam Nutr Res. 2007 Nov;77(6):359-68 [18622945.001]
  • [Cites] Contemp Clin Trials. 2008 Sep;29(5):711-9 [18586578.001]
  • [Cites] J Pediatr. 1995 Jul;127(1):63-7 [7608813.001]
  • [Cites] Prev Med. 1997 Nov-Dec;26(6):808-16 [9388792.001]
  • [Cites] N Engl J Med. 1998 Feb 19;338(8):499-505 [9468466.001]
  • [Cites] Blood. 1998 Jul 15;92(2):411-5 [9657739.001]
  • [Cites] Int J Cancer Suppl. 1998;11:35-9 [9876475.001]
  • [Cites] Osteoporos Int. 2005 Feb;16(2):163-71 [15185065.001]
  • [Cites] J Bone Miner Res. 2005 Apr;20(4):596-603 [15765178.001]
  • [Cites] J Am Coll Nutr. 2005 Apr;24(2):99-106 [15798076.001]
  • [Cites] J Clin Endocrinol Metab. 2005 Apr;90(4):1998-2004 [15671096.001]
  • [Cites] Am J Clin Nutr. 2005 Apr;81(4):923-33 [15817873.001]
  • [Cites] Pediatr Blood Cancer. 2005 Dec;45(7):881-91 [16035086.001]
  • [Cites] J Am Geriatr Soc. 2005 Nov;53(11):1875-80 [16274367.001]
  • [Cites] Ann Pharmacother. 2005 Dec;39(12):2086-90 [16249271.001]
  • [Cites] Am J Epidemiol. 2006 Jan 1;163(1):9-17 [16306312.001]
  • [Cites] N Engl J Med. 2006 Jan 12;354(2):166-78 [16407512.001]
  • [Cites] JAMA. 2006 Apr 5;295(13):1549-55 [16595758.001]
  • [Cites] J Clin Oncol. 2008 Oct 1;26(28):4639-45 [18824710.001]
  • [Cites] J Am Diet Assoc. 2008 Nov;108(11):1854-64 [18954575.001]
  • [Cites] PLoS Med. 2008 Oct 14;5(10):e196 [18922041.001]
  • [Cites] J Pediatr Hematol Oncol. 2008 Nov;30(11):815-22 [18989158.001]
  • [Cites] J Pediatr Hematol Oncol. 2009 Apr;31(4):259-66 [19346877.001]
  • [Cites] Joint Bone Spine. 2009 May;76(3):234-40 [19217816.001]
  • [Cites] J Clin Oncol. 2009 May 10;27(14):2339-55 [19364955.001]
  • [Cites] Prev Med. 2009 Aug-Sep;49(2-3):93-8 [19523482.001]
  • [Cites] J Bone Miner Res. 2004 Aug;19(8):1231-40 [15231009.001]
  • [Cites] Am J Clin Nutr. 2004 Oct;80(4):1075-80 [15447922.001]
  • [Cites] Blood. 2004 Nov 1;104(9):2690-6 [15251979.001]
  • [Cites] Lancet. 1991 Jan 12;337(8733):61-6 [1670723.001]
  • [Cites] Pediatr Radiol. 2000 Aug;30(8):558-65 [10993541.001]
  • (PMID = 20981691.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P30 CA021765; United States / NCI NIH HHS / CA / P30 CA-21765
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Calcium, Dietary; 1406-16-2 / Vitamin D
  • [Other-IDs] NLM/ NIHMS214402; NLM/ PMC3586793
  •  go-up   go-down


26. Langenau DM, Feng H, Berghmans S, Kanki JP, Kutok JL, Look AT: Cre/lox-regulated transgenic zebrafish model with conditional myc-induced T cell acute lymphoblastic leukemia. Proc Natl Acad Sci U S A; 2005 Apr 26;102(17):6068-73
ZFIN. ZFIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cre/lox-regulated transgenic zebrafish model with conditional myc-induced T cell acute lymphoblastic leukemia.
  • We have created a stable transgenic rag2-EGFP-mMyc zebrafish line that develops GFP-labeled T cell acute lymphoblastic leukemia (T-ALL), allowing visualization of the onset and spread of this disease.
  • Transgenic progeny from one of these lines can be induced to develop T-ALL by injecting Cre RNA into one-cell-stage embryos, demonstrating the utility of the Cre/lox system in the zebrafish and providing an essential step in preparing this model for chemical and genetic screens designed to identify modifiers of Myc-induced T-ALL.

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • COS Scholar Universe. author profiles.
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • SciCrunch. ZFIN: Data: Gene Expression .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Genes Dev. 1999 Oct 15;13(20):2658-69 [10541552.001]
  • [Cites] Development. 1996 Dec;123:1-36 [9007226.001]
  • [Cites] Immunogenetics. 2000 Sep;51(11):915-23 [11003385.001]
  • [Cites] Genes Chromosomes Cancer. 2000 Dec;29(4):371-7 [11066085.001]
  • [Cites] Semin Hematol. 2000 Oct;37(4):381-95 [11071360.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Nov 21;97(24):12965-9 [11087852.001]
  • [Cites] Genesis. 2001 Apr;29(4):156-62 [11309848.001]
  • [Cites] Nucleic Acids Res. 2001 Jun 1;29(11):E53-3 [11376165.001]
  • [Cites] Leukemia. 2001 Oct;15(10):1495-504 [11587205.001]
  • [Cites] Curr Biol. 2001 Oct 2;11(19):1481-91 [11591315.001]
  • [Cites] Oncogene. 2001 Nov 1;20(50):7447-52 [11704876.001]
  • [Cites] Hum Mutat. 2002 Jun;19(6):607-14 [12007217.001]
  • [Cites] Nat Genet. 2002 Jun;31(2):135-40 [12006978.001]
  • [Cites] Cancer Cell. 2002 Feb;1(1):75-87 [12086890.001]
  • [Cites] Cancer Cell. 2002 Mar;1(2):133-43 [12086872.001]
  • [Cites] Blood. 2002 Aug 1;100(3):991-7 [12130513.001]
  • [Cites] Mech Dev. 2002 Sep;117(1-2):243-8 [12204264.001]
  • [Cites] Science. 2003 Feb 7;299(5608):887-90 [12574629.001]
  • [Cites] Hum Mutat. 2003 Mar;21(3):176-81 [12619103.001]
  • [Cites] Nucleic Acids Res. 2003 Apr 15;31(8):e44 [12682379.001]
  • [Cites] Leukemia. 2003 May;17(5):887-93 [12750702.001]
  • [Cites] Semin Hematol. 2003 Oct;40(4):274-80 [14582078.001]
  • [Cites] Blood. 2004 Mar 1;103(5):1909-11 [14604958.001]
  • [Cites] Lancet. 2004 Feb 14;363(9408):535-6 [14975618.001]
  • [Cites] Nat Biotechnol. 2004 May;22(5):595-9 [15097998.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 May 11;101(19):7369-74 [15123839.001]
  • [Cites] Science. 2004 Oct 8;306(5694):269-71 [15472075.001]
  • [Cites] N Engl J Med. 1987 Jan 8;316(2):79-84 [3537802.001]
  • [Cites] Cell. 1989 Dec 22;59(6):1035-48 [2598259.001]
  • [Cites] Science. 1990 Jun 22;248(4962):1517-23 [2360047.001]
  • [Cites] Leukemia. 1991 Oct;5(10):839-40 [1961018.001]
  • [Cites] Science. 1994 Jul 1;265(5168):103-6 [8016642.001]
  • [Cites] Blood. 1994 Nov 1;84(9):3105-12 [7949183.001]
  • [Cites] Blood. 1995 May 1;85(9):2321-30 [7727766.001]
  • [Cites] Science. 1995 Sep 8;269(5229):1427-9 [7660125.001]
  • [Cites] Science. 1997 Nov 7;278(5340):1059-64 [9353180.001]
  • [Cites] Genes Dev. 1998 Aug 1;12(15):2424-33 [9694806.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Jan 11;102(2):407-12 [15630097.001]
  • [Cites] Blood. 2005 Apr 15;105(8):3278-85 [15618471.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Mar 28;97(7):3497-502 [10737801.001]
  • (PMID = 15827121.001).
  • [ISSN] 0027-8424
  • [Journal-full-title] Proceedings of the National Academy of Sciences of the United States of America
  • [ISO-abbreviation] Proc. Natl. Acad. Sci. U.S.A.
  • [Language] ENG
  • [Databank-accession-numbers] PIR/ AF398514
  • [Grant] United States / NCI NIH HHS / CA / P01 CA068484; United States / NCI NIH HHS / CA / P30 CA006516; United States / NCI NIH HHS / CA / CA-06516; United States / NCI NIH HHS / CA / CA-68484
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA-Binding Proteins; 0 / Extracellular Matrix Proteins; 0 / Genetic Markers; 0 / Nuclear Proteins; 0 / RAG2 protein, human; 0 / Rag2 protein, mouse; 0 / V(D)J recombination activating protein 2; 0 / enhanced green fluorescent protein; 147336-22-9 / Green Fluorescent Proteins; 149137-54-2 / Lox protein, mouse; EC 1.4.3.13 / Protein-Lysine 6-Oxidase; EC 2.7.7.- / Cre recombinase; EC 2.7.7.- / Integrases
  • [Other-IDs] NLM/ PMC1087915
  •  go-up   go-down


27. Riz I, Hawley RG: G1/S transcriptional networks modulated by the HOX11/TLX1 oncogene of T-cell acute lymphoblastic leukemia. Oncogene; 2005 Aug 25;24(36):5561-75
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] G1/S transcriptional networks modulated by the HOX11/TLX1 oncogene of T-cell acute lymphoblastic leukemia.
  • The HOX11/TLX1 homeobox gene is aberrantly expressed in a subset of T-cell acute lymphoblastic leukemia (T-ALL).
  • To distinguish potential HOX11 target genes from those characteristic of the stage of HOX11 leukemic arrest, we also performed gene expression analysis on Jurkat cells, genetically engineered to express exogenous HOX11.

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cell. 1990 Jan 12;60(1):167-76 [2153055.001]
  • [Cites] Science. 1991 Jul 5;253(5015):79-82 [1676542.001]
  • [Cites] Mol Cell Biol. 1998 Dec;18(12):7030-7 [9819390.001]
  • [Cites] Nature. 1998 Nov 12;396(6707):184-6 [9823900.001]
  • [Cites] Oncogene. 1998 Nov 19;17(20):2661-7 [9840930.001]
  • [Cites] Cell. 1998 Nov 25;95(5):605-14 [9845363.001]
  • [Cites] Oncogene. 1999 Jan 14;18(2):515-24 [9927208.001]
  • [Cites] J Biol Chem. 1999 May 28;274(22):15883-91 [10336493.001]
  • [Cites] Mol Cell Biol. 1999 Sep;19(9):6195-206 [10454566.001]
  • [Cites] J Biol Chem. 2000 Nov 17;275(46):35680-3 [11007767.001]
  • [Cites] J Biol Chem. 1999 Nov 5;274(45):31917-24 [10542219.001]
  • [Cites] Blood. 2000 Feb 1;95(3):745-55 [10648382.001]
  • [Cites] Cell. 2000 Mar 31;101(1):79-89 [10778858.001]
  • [Cites] Nat Genet. 2000 May;25(1):25-9 [10802651.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Jul 5;97(14):7963-8 [10859354.001]
  • [Cites] Genes Dev. 2000 Jul 1;14(13):1553-77 [10887150.001]
  • [Cites] J Immunol. 2000 Aug 15;165(4):1799-806 [10925257.001]
  • [Cites] Mol Cell Biol. 2000 Sep;20(18):6945-57 [10958690.001]
  • [Cites] J Exp Med. 2000 Sep 4;192(5):625-36 [10974029.001]
  • [Cites] Eur J Immunol. 2000 Dec;30(12):3422-31 [11093160.001]
  • [Cites] Biochem J. 2001 Feb 1;353(Pt 3):417-39 [11171037.001]
  • [Cites] J Exp Med. 2001 Apr 2;193(7):873-80 [11283160.001]
  • [Cites] Blood. 2001 Apr 15;97(8):2269-77 [11290587.001]
  • [Cites] Leuk Lymphoma. 2000 Oct;39(3-4):241-56 [11342305.001]
  • [Cites] Nat Immunol. 2001 Aug;2(8):691-7 [11477404.001]
  • [Cites] Nat Immunol. 2001 Sep;2(9):863-9 [11526403.001]
  • [Cites] Mol Cell Biol. 2001 Nov;21(21):7509-22 [11585930.001]
  • [Cites] Blood. 2001 Nov 1;98(9):2837-44 [11675358.001]
  • [Cites] Genes Dev. 2002 Jan 15;16(2):235-44 [11799066.001]
  • [Cites] Genes Dev. 2002 Jan 15;16(2):245-56 [11799067.001]
  • [Cites] J Cell Sci. 2002 Jan 15;115(Pt 2):241-56 [11839776.001]
  • [Cites] Mol Cell Biol. 2002 Mar;22(5):1352-9 [11839802.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Mar 19;99(6):3890-5 [11904439.001]
  • [Cites] Oncogene. 2002 Feb 28;21(10):1571-9 [11896586.001]
  • [Cites] J Biol Chem. 2002 Apr 5;277(14):11617-20 [11805123.001]
  • [Cites] J Biol Chem. 2002 May 31;277(22):19618-26 [11919195.001]
  • [Cites] AIDS Res Hum Retroviruses. 2002 May 20;18(8):591-604 [12036489.001]
  • [Cites] Cancer Cell. 2002 Feb;1(1):75-87 [12086890.001]
  • [Cites] Stem Cells. 2002;20(5):364-79 [12351808.001]
  • [Cites] Mol Cell. 2003 Apr;11(4):905-14 [12718877.001]
  • [Cites] Mol Cell. 2003 Apr;11(4):1101-8 [12718894.001]
  • [Cites] Genes Dev. 2003 May 1;17(9):1115-29 [12695333.001]
  • [Cites] J Biol Chem. 2003 May 9;278(19):16770-6 [12611887.001]
  • [Cites] J Biol Chem. 2003 May 23;278(21):19509-17 [12621062.001]
  • [Cites] EMBO Rep. 2003 Jun;4(6):575-80 [12776177.001]
  • [Cites] Blood. 2003 Jun 15;101(12):4717-24 [12586614.001]
  • [Cites] Blood. 2003 Jun 15;101(12):4966-74 [12586625.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Jul 8;100(14):8164-9 [12808131.001]
  • [Cites] Oncogene. 2003 Sep 4;22(38):5995-6004 [12955078.001]
  • [Cites] Nucleic Acids Res. 2003 Oct 1;31(19):5676-84 [14500831.001]
  • [Cites] Genome Biol. 2003;4(10):R69 [14519204.001]
  • [Cites] Mol Cell. 2003 Sep;12(3):735-46 [14527418.001]
  • [Cites] Oncogene. 2004 Feb 5;23(5):1088-97 [14716294.001]
  • [Cites] Cancer Cell. 2004 Feb;5(2):127-36 [14998489.001]
  • [Cites] Cancer Cell. 2004 Feb;5(2):177-89 [14998493.001]
  • [Cites] Genes Dev. 2004 Feb 15;18(4):357-68 [15004004.001]
  • [Cites] Nat Cell Biol. 2004 Apr;6(4):308-18 [15048125.001]
  • [Cites] J Immunol. 2004 May 1;172(9):5230-9 [15100261.001]
  • [Cites] Mol Cell Biol. 2004 May;24(10):4546-56 [15121871.001]
  • [Cites] J Biol Chem. 2004 Jun 4;279(23):23859-62 [15100215.001]
  • [Cites] J Biol Chem. 2004 Jul 16;279(29):30850-5 [15136563.001]
  • [Cites] J Immunol. 2004 Aug 1;173(3):1802-10 [15265911.001]
  • [Cites] Blood. 2004 Aug 15;104(4):923-32 [15155462.001]
  • [Cites] Oncogene. 2004 Sep 23;23(44):7378-90 [15286700.001]
  • [Cites] Science. 2004 Oct 8;306(5694):269-71 [15472075.001]
  • [Cites] Methods Mol Med. 2005;105:311-22 [15492404.001]
  • [Cites] J Immunol. 2002 Nov 15;169(10):5441-50 [12421919.001]
  • [Cites] Nat Rev Cancer. 2002 Dec;2(12):910-7 [12459729.001]
  • [Cites] Nucleic Acids Res. 2002 Dec 15;30(24):5465-75 [12490715.001]
  • [Cites] EMBO Rep. 2003 Jan;4(1):59-63 [12524522.001]
  • [Cites] Mol Cell Biol. 2003 Feb;23(4):1379-89 [12556497.001]
  • [Cites] J Neurochem. 2003 Jan;84(2):397-408 [12559002.001]
  • [Cites] Oncogene. 2003 Feb 20;22(7):992-1001 [12592386.001]
  • [Cites] Nat Struct Biol. 2003 Mar;10(3):175-81 [12567184.001]
  • [Cites] Trends Immunol. 2003 Apr;24(4):197-206 [12697452.001]
  • [Cites] Blood. 1991 Dec 1;78(11):2996-3003 [1683261.001]
  • [Cites] Mol Cell Biol. 1992 Aug;12(8):3346-55 [1630450.001]
  • [Cites] Mol Cell Biol. 1993 May;13(5):2822-34 [8386317.001]
  • [Cites] Proc Natl Acad Sci U S A. 1993 May 15;90(10):4431-5 [8099440.001]
  • [Cites] Oncogene. 1994 Jan;9(1):1-12 [7905617.001]
  • [Cites] Mol Cell Biol. 1994 Jul;14(7):4398-407 [7516466.001]
  • [Cites] EMBO J. 1994 Sep 1;13(17):4080-6 [8076603.001]
  • [Cites] Blood. 1995 Feb 1;85(3):675-84 [7833471.001]
  • [Cites] Nature. 1995 Mar 2;374(6517):70-4 [7870176.001]
  • [Cites] Oncogene. 1995 Sep 21;11(6):1113-23 [7566971.001]
  • [Cites] Gene Ther. 1994 Mar;1(2):136-8 [7584069.001]
  • [Cites] Semin Cancer Biol. 1995 Aug;6(4):195-202 [8541514.001]
  • [Cites] J Biol Chem. 1996 May 10;271(19):11059-62 [8626647.001]
  • [Cites] Mol Cell Biol. 1996 Jul;16(7):3454-64 [8668161.001]
  • [Cites] Cancer Res. 1997 Jan 15;57(2):337-45 [9000579.001]
  • [Cites] Science. 1997 Jan 31;275(5300):665-8 [9005852.001]
  • [Cites] Nature. 1997 Jan 30;385(6615):454-8 [9009195.001]
  • [Cites] Curr Biol. 1997 Jun 1;7(6):375-86 [9197238.001]
  • [Cites] EMBO J. 1997 Sep 15;16(18):5662-71 [9312025.001]
  • [Cites] J Biol Chem. 1997 Nov 7;272(45):28407-14 [9353299.001]
  • [Cites] Immunity. 1997 Nov;7(5):679-89 [9390691.001]
  • [Cites] Mol Cell Biol. 1998 Mar;18(3):1359-68 [9488451.001]
  • [Cites] Cell. 1998 Feb 20;92(4):463-73 [9491888.001]
  • [Cites] Blood. 1998 Aug 1;92(3):877-87 [9680355.001]
  • [Cites] EMBO J. 1998 Sep 15;17(18):5349-59 [9736613.001]
  • [Cites] Mol Cell Biol. 1998 Nov;18(11):6679-97 [9774682.001]
  • (PMID = 15897879.001).
  • [ISSN] 0950-9232
  • [Journal-full-title] Oncogene
  • [ISO-abbreviation] Oncogene
  • [Language] ENG
  • [Grant] United States / NHLBI NIH HHS / HL / R01HL65519; United States / NHLBI NIH HHS / HL / R01 HL066305-05; United States / NCRR NIH HHS / RR / R24RR16209; United States / NHLBI NIH HHS / HL / R01 HL065519; United States / NHLBI NIH HHS / HL / R01 HL066305; United States / NHLBI NIH HHS / HL / R01 HL066305-04; United States / NCRR NIH HHS / RR / R24 RR016209; United States / NHLBI NIH HHS / HL / HL066305-05; United States / NHLBI NIH HHS / HL / R01HL66305
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Homeodomain Proteins; 0 / Proto-Oncogene Proteins; 0 / Retinoblastoma Protein; 143275-75-6 / TLX1 protein, human; EC 2.7.11.1 / AKT1 protein, human; EC 2.7.11.1 / Protein-Serine-Threonine Kinases; EC 2.7.11.1 / Proto-Oncogene Proteins c-akt; EC 3.1.3.- / Phosphoric Monoester Hydrolases
  • [Other-IDs] NLM/ NIHMS51737; NLM/ PMC2408753
  •  go-up   go-down


28. Qin Y, Shi YK, He XH, Yang JL, Yang S, Yu YX, Li B, Wang QL, Zhou LQ, Sun Y: [Clinical features of 89 patients with primary non-Hodgkin's lymphoma of the tonsil]. Ai Zheng; 2006 Apr;25(4):481-5
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical features of 89 patients with primary non-Hodgkin's lymphoma of the tonsil].
  • BACKGROUND & OBJECTIVE: Head and neck lymphoma develops predominantly in the tonsil.
  • This study was to investigate the clinical features of primary non-Hodgkin's lymphoma (NHL) of the tonsil, and to explore possible ways to improve the prognosis and quality of life of the patients after treatment.
  • Stage I-II patients received radiochemotherapy-predominant treatment, whereas stage III-IV patients received chemotherapy-predominant treatment.
  • RESULTS: Of the 89 cases, 60 (67%) were diffuse large B-cell subtype, 11 (12%) were peripheral T-cell subtype, 5 (6%) were indolent lymphoma, 1 was anaplastic large T-cell lymphoma, and 1 was T lymphoblastic lymphoma; 81 (91%) were stage I-II disease.
  • The 5-year overall survival rate was 80%, that of stage I-II patients was 84%.
  • Diffuse large B-cell lymphoma is the most common pathologic subtype.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, Non-Hodgkin. Tonsillar Neoplasms
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Combined Modality Therapy. Cyclophosphamide / therapeutic use. Disease-Free Survival. Doxorubicin / therapeutic use. Drug Resistance, Neoplasm. Female. Follow-Up Studies. Humans. Lymphoma, Large B-Cell, Diffuse / drug therapy. Lymphoma, Large B-Cell, Diffuse / pathology. Lymphoma, Large B-Cell, Diffuse / radiotherapy. Lymphoma, T-Cell, Peripheral / drug therapy. Lymphoma, T-Cell, Peripheral / pathology. Lymphoma, T-Cell, Peripheral / radiotherapy. Male. Middle Aged. Neoplasm Recurrence, Local. Neoplasm Staging. Prednisone / therapeutic use. Quality of Life. Retrospective Studies. Survival Rate. Vincristine / therapeutic use. Young Adult

  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16613685.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


29. Lowe T, Luu T, Shen J, Bhatia S, Shibata S, Stein A, Somlo G: Male breast cancer 15 years after allogeneic hematopoietic cell transplantation including total body irradiation for recurrent acute lymphoblastic leukemia. Onkologie; 2008 May;31(5):266-9
MedlinePlus Health Information. consumer health - Male Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Male breast cancer 15 years after allogeneic hematopoietic cell transplantation including total body irradiation for recurrent acute lymphoblastic leukemia.
  • CASE REPORTS: We report here the case of a 34-year-old man who developed stage IIB node-positive breast cancer almost 15 years following total body irradiation and allogeneic hematopoietic cell transplantation for acute lymphoblastic leukemia.
  • [MeSH-major] Breast Neoplasms, Male / etiology. Hematopoietic Stem Cell Transplantation / adverse effects. Neoplasms, Radiation-Induced / etiology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy. Whole-Body Irradiation / adverse effects
  • [MeSH-minor] Adult. Humans. Longitudinal Studies. Male. Neoplasm Recurrence, Local


30. Ozçelik T, Ozkalemkaş F, Kocaeli H, Altundal Y, Ener B, Ali R, Ozkocaman V, Hakyemez B, Tunali A: [Successful treatment of neuroaspergillosis in a patient with acute lymphoblastic leukemia: role of surgery, systemic antifungal therapy and intracavitary therapy]. Mikrobiyol Bul; 2009 Jul;43(3):499-506
Hazardous Substances Data Bank. CASPOFUNGIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Successful treatment of neuroaspergillosis in a patient with acute lymphoblastic leukemia: role of surgery, systemic antifungal therapy and intracavitary therapy].
  • We report here a case of cerebral aspergillosis in a 34-years-old man with acute lymphoblastic leukaemia who was successfully treated with a combination of aggressive neurosurgery, intracavitary instillation of amphotericin B and voriconazole.
  • It is stated that in patients with neuroaspergillosis radical neurosurgery leads to better outcomes if performed at an earlier stage.
  • [MeSH-major] Antifungal Agents / therapeutic use. Aspergillus flavus / isolation & purification. Neuroaspergillosis / drug therapy. Neuroaspergillosis / surgery. Precursor Cell Lymphoblastic Leukemia-Lymphoma / complications
  • [MeSH-minor] Adult. Amphotericin B / administration & dosage. Amphotericin B / therapeutic use. Chemotherapy, Adjuvant. Drug Therapy, Combination. Echinocandins / administration & dosage. Echinocandins / therapeutic use. Fatal Outcome. Humans. Injections, Intraventricular. Male. Pyrimidines / administration & dosage. Pyrimidines / therapeutic use. Triazoles / administration & dosage. Triazoles / therapeutic use. Voriconazole

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Hazardous Substances Data Bank. AMPHOTERICIN B .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19795628.001).
  • [ISSN] 0374-9096
  • [Journal-full-title] Mikrobiyoloji bülteni
  • [ISO-abbreviation] Mikrobiyol Bul
  • [Language] tur
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Turkey
  • [Chemical-registry-number] 0 / Antifungal Agents; 0 / Echinocandins; 0 / Pyrimidines; 0 / Triazoles; 7XU7A7DROE / Amphotericin B; F0XDI6ZL63 / caspofungin; JFU09I87TR / Voriconazole
  •  go-up   go-down


31. Wessels G, Bernard Hesseling P: Perspectives of the management of childhood lymphoma: experience at Tygerberg Hospital, Western Cape, South Africa. Transfus Apher Sci; 2005 Feb;32(1):27-31
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Perspectives of the management of childhood lymphoma: experience at Tygerberg Hospital, Western Cape, South Africa.
  • Non-Hodgkin's Lymphoma (NHL) in children, however, differs from NHL in adults with respect to the classification, natural history, management and course.
  • Lymphoblastic or T-cell NHL is treated with regimens normally used for acute lymphoblastic leukaemia (e.g.
  • BFM protocols) or modified leukaemia treatments for leukaemia-lymphoma syndromes (e.g. LSA2L2).
  • The majority of patients had stage III and IV disease.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hodgkin Disease / therapy. Lymphoma, Non-Hodgkin / therapy
  • [MeSH-minor] Adult. Bleomycin / administration & dosage. Blood Transfusion. Child. Combined Modality Therapy. Dacarbazine / administration & dosage. Disease-Free Survival. Doxorubicin / administration & dosage. Humans. Mechlorethamine / administration & dosage. Prednisone / administration & dosage. Procarbazine / administration & dosage. Recurrence. South Africa. Time Factors. Vinblastine / administration & dosage. Vincristine / administration & dosage

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. NITROGEN MUSTARD N-OXIDE HYDROCHLORIDE .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • Hazardous Substances Data Bank. MECHLORETHAMINE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. MECHLORETHAMINE HYDROCHLORIDE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. PROCARBAZINE .
  • Hazardous Substances Data Bank. VINBLASTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15737871.001).
  • [ISSN] 1473-0502
  • [Journal-full-title] Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis
  • [ISO-abbreviation] Transfus. Apher. Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 35S93Y190K / Procarbazine; 50D9XSG0VR / Mechlorethamine; 5J49Q6B70F / Vincristine; 5V9KLZ54CY / Vinblastine; 7GR28W0FJI / Dacarbazine; 80168379AG / Doxorubicin; VB0R961HZT / Prednisone; ABVD protocol; MOPP protocol
  • [Number-of-references] 15
  •  go-up   go-down


32. Alexander BM, Wechsler D, Braun TM, Levine J, Herman J, Yanik G, Hutchinson R, Pierce LJ: Utility of cranial boost in addition to total body irradiation in the treatment of high risk acute lymphoblastic leukemia. Int J Radiat Oncol Biol Phys; 2005 Nov 15;63(4):1191-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Utility of cranial boost in addition to total body irradiation in the treatment of high risk acute lymphoblastic leukemia.
  • PURPOSE: Total body irradiation (TBI) as part of a conditioning regimen before hematopoietic stem cell transplant (HSCT) is an important component in the management of acute lymphoblastic leukemia (ALL) that has relapsed or has other certain high-risk features.
  • Data including patient demographics, clinical features at presentation, conditioning regimen, donor source, use of a cranial boost, remission stage at transplant, histologic subtype, cytogenetics, and extramedullary site of presentation were retrospectively collected and correlated with the risk of subsequent CNS recurrence.
  • [MeSH-major] Brain Neoplasms / prevention & control. Cranial Irradiation. Precursor Cell Lymphoblastic Leukemia-Lymphoma / prevention & control. Whole-Body Irradiation
  • [MeSH-minor] Adolescent. Adult. Bone Marrow Transplantation. Child. Child, Preschool. Disease Progression. Female. Hematopoietic Stem Cell Transplantation. Humans. Male. Recurrence. Retrospective Studies. Transplantation Conditioning / methods


33. Snuderl M, Kolman OK, Chen YB, Hsu JJ, Ackerman AM, Dal Cin P, Ferry JA, Harris NL, Hasserjian RP, Zukerberg LR, Abramson JS, Hochberg EP, Lee H, Lee AI, Toomey CE, Sohani AR: B-cell lymphomas with concurrent IGH-BCL2 and MYC rearrangements are aggressive neoplasms with clinical and pathologic features distinct from Burkitt lymphoma and diffuse large B-cell lymphoma. Am J Surg Pathol; 2010 Mar;34(3):327-40
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] B-cell lymphomas with concurrent IGH-BCL2 and MYC rearrangements are aggressive neoplasms with clinical and pathologic features distinct from Burkitt lymphoma and diffuse large B-cell lymphoma.
  • B-cell lymphomas with concurrent IGH-BCL2 and MYC rearrangements, also known as "double-hit" lymphomas (DHL), are rare neoplasms characterized by highly aggressive clinical behavior, complex karyotypes, and a spectrum of pathologic features overlapping with Burkitt lymphoma (BL), diffuse large B-cell lymphoma (DLBCL) and B-lymphoblastic lymphoma/leukemia (B-LBL).
  • Six patients had a history of grade 1 to 2 follicular lymphoma; review of the prior biopsy specimens in 2 of 5 cases revealed blastoid morphology.
  • Eighteen patients had Ann Arbor stage 3 or 4 disease and all had elevated serum lactate dehydrogenase (LDH) levels at presentation.
  • Twelve DHL cases (60%) were classified as B-cell lymphoma, unclassifiable, with features intermediate between DLBCL and BL, 7 cases (35%) as DLBCL, not otherwise specified, and 1 case as B-LBL.
  • [MeSH-major] Burkitt Lymphoma / genetics. Gene Expression Regulation, Neoplastic. Gene Rearrangement, B-Lymphocyte, Heavy Chain. Genes, Immunoglobulin Heavy Chain. Lymphoma, B-Cell / genetics. Lymphoma, Large B-Cell, Diffuse / genetics. Proto-Oncogene Proteins c-bcl-2 / genetics. Proto-Oncogene Proteins c-myc / genetics
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols. Child. Drug Resistance, Neoplasm. Female. Humans. Immunophenotyping. In Situ Hybridization, Fluorescence. Kaplan-Meier Estimate. Karyotyping. Male. Middle Aged. Neoplasm Staging. Polymerase Chain Reaction. Predictive Value of Tests. Proportional Hazards Models. Retrospective Studies. Risk Assessment. Terminology as Topic. Time Factors. Treatment Outcome. World Health Organization. Young Adult

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • Genetic Alliance. consumer health - B-Cell Lymphomas.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Surg Pathol. 2000 Apr;24(4):525-34 [10757399.001]
  • [Cites] Leukemia. 2000 Nov;14(11):1960-6 [11069032.001]
  • [Cites] Cancer Genet Cytogenet. 2000 Nov;123(1):52-4 [11120335.001]
  • [Cites] Cancer Genet Cytogenet. 2001 Apr 1;126(1):45-51 [11343778.001]
  • [Cites] Arch Pathol Lab Med. 2003 May;127(5):610-3 [12708908.001]
  • [Cites] Blood. 2004 Jan 1;103(1):275-82 [14504078.001]
  • [Cites] Arch Pathol Lab Med. 2004 Feb;128(2):210-3 [14736281.001]
  • [Cites] Int J Hematol. 2004 Jun;79(5):474-9 [15239399.001]
  • [Cites] Blood. 1983 Nov;62(5):1142-6 [6605167.001]
  • [Cites] Proc Natl Acad Sci U S A. 1984 Nov;81(22):7166-70 [6334305.001]
  • [Cites] Am J Clin Pathol. 1986 May;85(5):636-40 [3486584.001]
  • [Cites] N Engl J Med. 1987 Nov 5;317(19):1185-9 [3657890.001]
  • [Cites] N Engl J Med. 1988 May 26;318(21):1373-8 [3285208.001]
  • [Cites] Oncogene. 1988 May;2(5):431-5 [3131717.001]
  • [Cites] J Clin Invest. 1989 Nov;84(5):1454-9 [2509518.001]
  • [Cites] Genes Chromosomes Cancer. 1990 Jul;2(2):147-58 [2278969.001]
  • [Cites] Oncogene. 1991 Jan;6(1):145-8 [1992441.001]
  • [Cites] Leukemia. 1991 Jan;5(1):83-7 [1999960.001]
  • [Cites] Leukemia. 1991 Jun;5(6):473-8 [1711639.001]
  • [Cites] Hematol Oncol. 1991 Mar-Apr;9(2):63-78 [1869243.001]
  • [Cites] Ann Hematol. 1991 Nov;63(5):282-7 [1958753.001]
  • [Cites] Ann Hematol. 1992 Feb;64(2):101-4 [1554791.001]
  • [Cites] N Engl J Med. 1993 Sep 30;329(14):987-94 [8141877.001]
  • [Cites] Leukemia. 1994 Apr;8(4):560-3 [8152251.001]
  • [Cites] Cancer Genet Cytogenet. 1994 Jun;74(2):87-94 [8019967.001]
  • [Cites] Am J Clin Pathol. 1995 Apr;103(4):472-8 [7726146.001]
  • [Cites] Ann Oncol. 1998 Jan;9(1):55-61 [9541684.001]
  • [Cites] Blood. 1998 Nov 1;92(9):3152-62 [9787151.001]
  • [Cites] J Clin Oncol. 1999 May;17(5):1558-67 [10334544.001]
  • [Cites] Am J Surg Pathol. 2005 Jan;29(1):121-4 [15613866.001]
  • [Cites] Genes Chromosomes Cancer. 2005 Aug;43(4):414-23 [15852472.001]
  • [Cites] Hum Pathol. 2005 May;36(5):571-5 [15948125.001]
  • [Cites] Am J Surg Pathol. 2005 Aug;29(8):1086-94 [16006805.001]
  • [Cites] Am J Surg Pathol. 2005 Nov;29(11):1490-6 [16224216.001]
  • [Cites] Leukemia. 2005 Dec;19(12):2313-23 [16193090.001]
  • [Cites] Am J Surg Pathol. 2005 Dec;29(12):1652-60 [16327438.001]
  • [Cites] Mod Pathol. 2006 Jan;19(1):25-33 [16258503.001]
  • [Cites] N Engl J Med. 2006 Jun 8;354(23):2419-30 [16760442.001]
  • [Cites] N Engl J Med. 2006 Jun 8;354(23):2431-42 [16760443.001]
  • [Cites] Br J Haematol. 2006 Aug;134(3):294-301 [16848772.001]
  • [Cites] Cancer Genet Cytogenet. 2006 Nov;171(1):52-6 [17074591.001]
  • [Cites] J Clin Pathol. 2007 Sep;60(9):1061-4 [17182663.001]
  • [Cites] Haematologica. 2007 Oct;92(10):1335-42 [18024371.001]
  • [Cites] Am J Clin Pathol. 2008 Jan;129(1):157-66 [18089500.001]
  • [Cites] Curr Protoc Hum Genet. 2007 Jan;Chapter 8:Unit 8.8 [18428417.001]
  • [Cites] Haematologica. 2008 Sep;93(9):1327-34 [18698080.001]
  • [Cites] Blood. 2008 Sep 15;112(6):2248-60 [18612102.001]
  • [Cites] Am J Surg Pathol. 2008 Nov;32(11):1593-607 [18753947.001]
  • [Cites] Br J Haematol. 2009 Mar;144(5):716-25 [19120369.001]
  • [Cites] Leukemia. 2009 Feb;23(2):225-34 [18923440.001]
  • [Cites] Leukemia. 2009 Apr;23(4):777-83 [19151788.001]
  • [Cites] Haematologica. 2009 Jul;94(7):935-43 [19535347.001]
  • [Cites] Blood. 2009 Sep 10;114(11):2273-9 [19597184.001]
  • [Cites] Haematologica. 2007 Oct;92(10):1297-301 [18024366.001]
  • (PMID = 20118770.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R37 CA076404; United States / NIGMS NIH HHS / GM / T32 GM074897; United States / NIGMS NIH HHS / GM / T32 GM074897-07
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / MYC protein, human; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / Proto-Oncogene Proteins c-myc
  • [Other-IDs] NLM/ NIHMS305320; NLM/ PMC3152212
  •  go-up   go-down


34. Diviné M, Casassus P, Koscielny S, Bosq J, Sebban C, Le Maignan C, Stamattoulas A, Dupriez B, Raphaël M, Pico JL, Ribrag V, GELA, GOELAMS: Burkitt lymphoma in adults: a prospective study of 72 patients treated with an adapted pediatric LMB protocol. Ann Oncol; 2005 Dec;16(12):1928-35
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Burkitt lymphoma in adults: a prospective study of 72 patients treated with an adapted pediatric LMB protocol.
  • BACKGROUND: We conducted a phase II study to evaluate in 72 adult patients the efficacy of the intensive LMB chemotherapy regimen, previously reported by the Société Française d'Oncologie Pédiatrique for children with Burkitt lymphoma and L3 acute lymphoblastic leukemia.
  • Group A (resected stage I and abdominal stage II disease) received three courses of vincristine, cyclophosphamide, doxorubicin and prednisone.
  • CONCLUSION: Patients with advanced-stage Burkitt lymphoma, including those with bone marrow and/or central nervous system involvement, can be cured with a short-term intensive chemotherapy regime tailored to the tumor burden.

  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. HYDROCORTISONE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. LEUCOVORIN .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16284057.001).
  • [ISSN] 0923-7534
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study
  • [Publication-country] England
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; Q573I9DVLP / Leucovorin; VB0R961HZT / Prednisone; WI4X0X7BPJ / Hydrocortisone; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


35. Salzburg J, Burkhardt B, Zimmermann M, Wachowski O, Woessmann W, Oschlies I, Klapper W, Wacker HH, Ludwig WD, Niggli F, Mann G, Gadner H, Riehm H, Schrappe M, Reiter A: Prevalence, clinical pattern, and outcome of CNS involvement in childhood and adolescent non-Hodgkin's lymphoma differ by non-Hodgkin's lymphoma subtype: a Berlin-Frankfurt-Munster Group Report. J Clin Oncol; 2007 Sep 1;25(25):3915-22
MedlinePlus Health Information. consumer health - Head and Neck Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prevalence, clinical pattern, and outcome of CNS involvement in childhood and adolescent non-Hodgkin's lymphoma differ by non-Hodgkin's lymphoma subtype: a Berlin-Frankfurt-Munster Group Report.
  • PURPOSE: We analyzed the prevalence, clinical pattern, and prognostic impact of CNS involvement in a large cohort of children and adolescents diagnosed with non-Hodgkin's lymphoma (NHL), with special attention to differences according to NHL subtype.
  • RESULTS: CNS involvement was diagnosed in 141 (5.9%) of 2,381 patients and was associated with an advanced stage of NHL.
  • The percentage of CNS-positive patients was 8.8% for Burkitt's lymphoma/Burkitt's leukemia (BL/B-ALL), 5.4% for precursor B-lymphoblastic lymphoma (pB-LBL), 3.3% for anaplastic large-cell lymphoma, 3.2% for T-cell-LBL, 2.6% for diffuse large B-cell lymphoma, and 0% for primary mediastinal large B-cell NHL (P < .001).
  • Although CNS disease had no impact on pEFS for advanced-stage T-LBL patients, CNS-positive patients with BL/B-ALL had a worse average outcome than CNS-negative patients with stage IV BL/B-ALL (60% +/- 5% v 81% +/- 3%; P < .001).
  • In multivariate analysis, CNS disease was the strongest predictor for relapse in BL/B-ALL patients with advanced-stage disease.
  • [MeSH-major] Brain Neoplasms / epidemiology. Head and Neck Neoplasms / epidemiology. Lymphoma, Non-Hodgkin / classification. Lymphoma, Non-Hodgkin / epidemiology
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Disease-Free Survival. Epidural Neoplasms / epidemiology. Epidural Neoplasms / therapy. Female. Germany / epidemiology. Humans. Infant. Infant, Newborn. Male. Multivariate Analysis. Neoplasm Recurrence, Local. Neoplasm Staging. Prevalence. Prognosis. Treatment Failure. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17761975.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


36. Shabani M, Asgarian-Omran H, Vossough P, Sharifian RA, Faranoush M, Ghragozlou S, Khoshnoodi J, Roohi A, Jeddi-Tehrani M, Mellstedt H, Rabbani H, Shokri F: Expression profile of orphan receptor tyrosine kinase (ROR1) and Wilms' tumor gene 1 (WT1) in different subsets of B-cell acute lymphoblastic leukemia. Leuk Lymphoma; 2008 Jul;49(7):1360-7
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression profile of orphan receptor tyrosine kinase (ROR1) and Wilms' tumor gene 1 (WT1) in different subsets of B-cell acute lymphoblastic leukemia.
  • In the present study, the expression profile of ROR1 and WT1 was investigated in different immunophenotypic subsets of B-cell acute lymphoblastic leukemia (B-ALL) patients.
  • Our results suggest that expression of ROR1 and WT1 in B-ALL is associated with the differentiation stage of the leukemic cells.
  • [MeSH-major] Burkitt Lymphoma / pathology. Receptor Protein-Tyrosine Kinases / genetics. WT1 Proteins / genetics
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Gene Expression Profiling. Humans. Immunophenotyping. Infant. Iran. RNA, Neoplasm / analysis. Receptor Tyrosine Kinase-like Orphan Receptors. Reverse Transcriptase Polymerase Chain Reaction

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Wilms' tumor.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18604725.001).
  • [ISSN] 1029-2403
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / RNA, Neoplasm; 0 / WT1 Proteins; EC 2.7.10.1 / ROR1 protein, human; EC 2.7.10.1 / Receptor Protein-Tyrosine Kinases; EC 2.7.10.1 / Receptor Tyrosine Kinase-like Orphan Receptors
  •  go-up   go-down


37. Guo Z, Dose M, Kovalovsky D, Chang R, O'Neil J, Look AT, von Boehmer H, Khazaie K, Gounari F: Beta-catenin stabilization stalls the transition from double-positive to single-positive stage and predisposes thymocytes to malignant transformation. Blood; 2007 Jun 15;109(12):5463-72
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Beta-catenin stabilization stalls the transition from double-positive to single-positive stage and predisposes thymocytes to malignant transformation.
  • We show here that activated beta-catenin stalls the developmental transition from the double-positive (DP) to the single-positive (SP) thymocyte stage and predisposes DP thymocytes to transformation. beta-Catenin-induced thymic lymphomas have a leukemic arrest at the early DP stage.
  • Lymphomagenesis requires Rag activity, which peaks at this developmental stage, as well as additional secondary genetic events.
  • Thus, beta-catenin activation may provide a mechanism for the induction of T-cell-acute lymphoblastic leukemia (T-ALL) that does not depend on Notch activation.

  • COS Scholar Universe. author profiles.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] EMBO J. 1996 Sep 2;15(17):4526-36 [8887544.001]
  • [Cites] Science. 1998 Apr 24;280(5363):596-9 [9554852.001]
  • [Cites] EMBO J. 1997 Feb 3;16(3):441-50 [9034327.001]
  • [Cites] EMBO J. 1999 Nov 1;18(21):5931-42 [10545105.001]
  • [Cites] Mol Cell Biol. 2000 Mar;20(6):2228-38 [10688669.001]
  • [Cites] Curr Opin Immunol. 2000 Apr;12(2):166-72 [10712939.001]
  • [Cites] EMBO J. 1997 Jul 1;16(13):3797-804 [9233789.001]
  • [Cites] Immunity. 1998 Jan;8(1):11-20 [9462507.001]
  • [Cites] Cell Growth Differ. 1998 Feb;9(2):131-8 [9486849.001]
  • [Cites] J Biol Chem. 1998 May 1;273(18):10823-6 [9556553.001]
  • [Cites] J Immunol. 1998 Oct 15;161(8):3984-91 [9780167.001]
  • [Cites] EMBO J. 1999 May 17;18(10):2823-35 [10329628.001]
  • [Cites] Mol Cell Biol. 1999 Jun;19(6):4414-22 [10330181.001]
  • [Cites] Mol Cell. 1999 Aug;4(2):199-207 [10488335.001]
  • [Cites] Nat Immunol. 2005 Aug;6(8):800-9 [16025118.001]
  • [Cites] Blood. 2006 Jan 15;107(2):781-5 [16166587.001]
  • [Cites] Blood. 2006 Apr 15;107(8):3131-7 [16384926.001]
  • [Cites] Blood. 2006 May 15;107(10):4115-21 [16449526.001]
  • [Cites] Genes Dev. 2006 Aug 1;20(15):2096-109 [16847353.001]
  • [Cites] Eur J Immunol. 2006 Sep;36(9):2376-83 [16897815.001]
  • [Cites] Nat Immunol. 2006 Oct;7(10):1037-47 [16951686.001]
  • [Cites] Nat Immunol. 2006 Oct;7(10):1048-56 [16951689.001]
  • [Cites] Leukemia. 2006 Nov;20(11):1967-77 [16990763.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Nov 28;103(48):18261-6 [17114293.001]
  • [Cites] Blood. 2012 Oct 25;120(17):3625 [22898606.001]
  • [Cites] EMBO J. 2000 Jul 3;19(13):3337-48 [10880446.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Jan 2;98(1):31-6 [11134512.001]
  • [Cites] Immunity. 2001 Jan;14(1):45-55 [11163229.001]
  • [Cites] Eur J Immunol. 2001 Jan;31(1):285-93 [11265645.001]
  • [Cites] Nat Immunol. 2001 Mar;2(3):235-41 [11224523.001]
  • [Cites] Immunity. 2001 Mar;14(3):253-64 [11290335.001]
  • [Cites] Nat Immunol. 2001 Aug;2(8):691-7 [11477404.001]
  • [Cites] Nat Immunol. 2001 Sep;2(9):863-9 [11526403.001]
  • [Cites] Cell. 2002 Apr;109 Suppl:S13-9 [11983149.001]
  • [Cites] Oncogene. 2002 May 13;21(21):3414-21 [12032779.001]
  • [Cites] Cancer Cell. 2002 Feb;1(1):75-87 [12086890.001]
  • [Cites] Curr Opin Immunol. 2003 Apr;15(2):204-8 [12633671.001]
  • [Cites] Nature. 2003 May 22;423(6938):409-14 [12717450.001]
  • [Cites] Nat Immunol. 2003 Dec;4(12):1177-82 [14608382.001]
  • [Cites] Cancer Cell. 2004 Jan;5(1):91-102 [14749129.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Mar 2;101(9):3118-23 [14973184.001]
  • [Cites] Int J Cancer. 2004 Jun 20;110(3):336-42 [15095297.001]
  • [Cites] Cancer Cell. 2004 Jun;5(6):587-96 [15193261.001]
  • [Cites] Semin Cancer Biol. 2004 Oct;14(5):329-40 [15288258.001]
  • [Cites] N Engl J Med. 2004 Aug 12;351(7):657-67 [15306667.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Aug 24;101(34):12682-7 [15314234.001]
  • [Cites] Science. 2004 Oct 8;306(5694):269-71 [15472075.001]
  • [Cites] Nature. 1989 Nov 9;342(6246):185-9 [2572968.001]
  • [Cites] Cell. 1991 May 31;65(5):737-52 [1904008.001]
  • [Cites] Nature. 1994 Jan 6;367(6458):80-3 [7906389.001]
  • [Cites] J Exp Med. 1994 Jul 1;180(1):25-34 [8006585.001]
  • [Cites] Nature. 1995 Jun 29;375(6534):795-8 [7596413.001]
  • [Cites] J Exp Med. 1996 May 1;183(5):2283-91 [8642337.001]
  • [Cites] J Immunol. 1996 Aug 1;157(3):978-83 [8757600.001]
  • [Cites] EMBO J. 1998 Mar 2;17(5):1371-84 [9482734.001]
  • [Cites] Oncogene. 1996 Nov 21;13(10):2205-12 [8950988.001]
  • (PMID = 17317856.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] ENG
  • [Grant] United States / NIDDK NIH HHS / DK / P30 DK34928; United States / NCI NIH HHS / CA / R01 CA104547; United States / NIDDK NIH HHS / DK / P30 DK034928; United States / NCI NIH HHS / CA / R01 CA104547-01A1; United States / NIAID NIH HHS / AI / R01 AI059676-01; United States / NIAID NIH HHS / AI / R01 AI059676
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Homeodomain Proteins; 0 / Myc protein, mouse; 0 / Proto-Oncogene Proteins c-myc; 0 / Receptors, Notch; 0 / beta Catenin; 128559-51-3 / RAG-1 protein
  • [Other-IDs] NLM/ PMC1890819
  •  go-up   go-down


38. Marinovic D, Dorgeret S, Lescoeur B, Alberti C, Noel M, Czernichow P, Sebag G, Vilmer E, Léger J: Improvement in bone mineral density and body composition in survivors of childhood acute lymphoblastic leukemia: a 1-year prospective study. Pediatrics; 2005 Jul;116(1):e102-8
Hazardous Substances Data Bank. CALCIUM, ELEMENTAL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Improvement in bone mineral density and body composition in survivors of childhood acute lymphoblastic leukemia: a 1-year prospective study.
  • OBJECTIVES: Abnormalities in bone mineral density (BMD), body composition, and bone metabolism have been reported in children who were treated for acute lymphoblastic leukemia (ALL) during and after completion of therapy.
  • Two control subjects (n = 74) who were matched for gender, age, and pubertal stage were also longitudinally investigated for body composition for 1 year.
  • CONCLUSIONS: A significant increase in TB BMD and a tendency to a lesser increase in percentage of body fat mass were observed during the study period in ALL patients as compared with chronological age-, gender-, and pubertal stage-matched control subjects.
  • [MeSH-major] Body Composition. Bone Density. Precursor Cell Lymphoblastic Leukemia-Lymphoma / metabolism
  • [MeSH-minor] Absorptiometry, Photon. Adolescent. Adult. Body Mass Index. Bone and Bones / metabolism. Calcium / blood. Child. Child, Preschool. Exercise. Female. Humans. Longitudinal Studies. Lumbar Vertebrae / metabolism. Male


39. Lee S, Kim YJ, Chung NG, Lim J, Lee DG, Kim HJ, Min CK, Lee JW, Min WS, Kim CC: The extent of minimal residual disease reduction after the first 4-week imatinib therapy determines outcome of allogeneic stem cell transplantation in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia. Cancer; 2009 Feb 1;115(3):561-70
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The extent of minimal residual disease reduction after the first 4-week imatinib therapy determines outcome of allogeneic stem cell transplantation in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia.
  • BACKGROUND: Previously, the authors demonstrated the positive impact of imatinib on the outcome of allogeneic stem cell transplantation in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph-positive ALL).
  • Here, the authors analyzed for risk factors that affect transplantation outcome, and they focused particularly on the prognostic relevance of minimal residual disease level at each treatment stage.
  • The frequency of achieving a reduction in BCR-ABL transcript levels of at least 3 log at this stage was 36 (69.2%).
  • [MeSH-major] Neoplasm, Residual / diagnosis. Piperazines / therapeutic use. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy. Pyrimidines / therapeutic use. Stem Cell Transplantation
  • [MeSH-minor] Adolescent. Adult. Benzamides. Disease-Free Survival. Female. Follow-Up Studies. Humans. Imatinib Mesylate. Male. Middle Aged. Prognosis. Recurrence. Risk Factors. Time Factors

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Transplantation.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. IMATINIB MESYLATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19117346.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Benzamides; 0 / Piperazines; 0 / Pyrimidines; 8A1O1M485B / Imatinib Mesylate
  •  go-up   go-down


40. Maruyama D, Watanabe T, Beppu Y, Kobayashi Y, Kim SW, Tanimoto K, Makimoto A, Kagami Y, Terauchi T, Matsuno Y, Tobinai K: Primary bone lymphoma: a new and detailed characterization of 28 patients in a single-institution study. Jpn J Clin Oncol; 2007 Mar;37(3):216-23
MedlinePlus Health Information. consumer health - Lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary bone lymphoma: a new and detailed characterization of 28 patients in a single-institution study.
  • BACKGROUND: The incidence of primary bone lymphoma (PBL) is so rare that many of its aspects remain unknown.
  • Although 19 (68%) patients had diffuse large B-cell lymphoma (DLBCL), other histopathological subtypes (three B-lymphoblastic lymphoma, two anaplastic large cell lymphoma, two indolent B-cell lymphoma, one NK/T-cell lymphoma (NTCL) and one Hodgkin lymphoma) were also included.
  • While 68% of patients had stage IV disease, none of them showed bone marrow involvement at their initial diagnosis.
  • [MeSH-major] Bone Neoplasms / pathology. Lymphoma / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Child. Child, Preschool. Female. Hodgkin Disease / pathology. Humans. Lymphoma, B-Cell / pathology. Male. Middle Aged. Neoplasm Staging. Retrospective Studies. Survival Rate. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17472971.001).
  • [ISSN] 1465-3621
  • [Journal-full-title] Japanese journal of clinical oncology
  • [ISO-abbreviation] Jpn. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  •  go-up   go-down


41. Babusíková O, Zelezníková T, Mlcáková A, Kusenda J, Stevulová L: The knowledge on the 3rd type hematogones could contribute to more precise detection of small numbers of precursor B-acute lymphoblastic leukemia. Neoplasma; 2005;52(6):502-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The knowledge on the 3rd type hematogones could contribute to more precise detection of small numbers of precursor B-acute lymphoblastic leukemia.
  • Bone marrow hematogones were separately assessed as hematogones 1 population of early stage and hematogones 2 of mid-stage precursor B-cells, respectively.
  • Quantitative immunophenotyping of this study completed the percent antigen expression data in two main hematogone subtypes and lymphocytes in 16 bone marrow specimens and precursor B-ALL lymphoblasts in some samples.
  • [MeSH-major] Antigens, CD / analysis. B-Lymphocytes / immunology. Bone Marrow / immunology. Bone Marrow Cells / cytology. Burkitt Lymphoma / diagnosis. Immunophenotyping
  • [MeSH-minor] Adolescent. Adult. Age Distribution. Aged. Aged, 80 and over. Child. Child, Preschool. Female. Flow Cytometry. Humans. Infant. Male. Middle Aged. Prognosis. Prospective Studies

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16284697.001).
  • [ISSN] 0028-2685
  • [Journal-full-title] Neoplasma
  • [ISO-abbreviation] Neoplasma
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Slovakia
  • [Chemical-registry-number] 0 / Antigens, CD
  •  go-up   go-down


42. Owens BM, Hawley TS, Spain LM, Kerkel KA, Hawley RG: TLX1/HOX11-mediated disruption of primary thymocyte differentiation prior to the CD4+CD8+ double-positive stage. Br J Haematol; 2006 Jan;132(2):216-29
Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] TLX1/HOX11-mediated disruption of primary thymocyte differentiation prior to the CD4+CD8+ double-positive stage.
  • The TLX1/HOX11 homeobox gene is frequently activated in T-cell acute lymphoblastic leukaemia (T-ALL) by the t(10;14)(q24;q11) and t(7;10)(q35;q24) chromosomal translocations or by as yet unknown transcriptional mechanisms in the absence of 10q24 cytogenetic abnormalities.
  • Interestingly, enforced expression of TLX1 disrupted the differentiation of murine fetal liver precursors and human cord blood CD34(+) stem/progenitor cells prior to the DP thymocyte stage.

  • COS Scholar Universe. author profiles.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Oncogene. 1995 Oct 5;11(7):1333-8 [7478554.001]
  • [Cites] Science. 1995 Sep 29;269(5232):1875-7 [7569929.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Oct 24;92(22):10302-6 [7479772.001]
  • [Cites] Gene Ther. 1994 Mar;1(2):136-8 [7584069.001]
  • [Cites] Biochemistry. 1995 Nov 7;34(44):14601-8 [7578067.001]
  • [Cites] Cell. 1996 Apr 5;85(1):27-37 [8620534.001]
  • [Cites] Blood. 1996 Mar 15;87(6):2180-6 [8630377.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Sep 17;93(19):10297-302 [8816794.001]
  • [Cites] Cancer Res. 1997 Jan 15;57(2):337-45 [9000579.001]
  • [Cites] Nature. 1997 Jan 30;385(6615):454-8 [9009195.001]
  • [Cites] Immunity. 1997 Mar;6(3):265-72 [9075927.001]
  • [Cites] Cell. 1997 Jun 27;89(7):1011-9 [9215624.001]
  • [Cites] Cell. 1997 Jun 27;89(7):1033-41 [9215626.001]
  • [Cites] Gene Ther. 1997 Oct;4(10):1013-22 [9415306.001]
  • [Cites] J Immunol. 1998 Jun 15;160(12):5735-41 [9637482.001]
  • [Cites] Blood. 1998 Aug 1;92(3):877-87 [9680355.001]
  • [Cites] Immunity. 1999 May;10(5):537-46 [10367899.001]
  • [Cites] J Immunol. 1999 Aug 1;163(3):1334-41 [10415032.001]
  • [Cites] Blood. 2004 Dec 15;104(13):4173-80 [15054041.001]
  • [Cites] Oncogene. 2005 Apr 18;24(17):2899-908 [15838523.001]
  • [Cites] Blood. 2005 Jun 15;105(12):4849-52 [15713800.001]
  • [Cites] Blood. 2005 Jul 1;106(1):274-86 [15774621.001]
  • [Cites] Leukemia. 2005 Sep;19(9):1705-8 [15990867.001]
  • [Cites] Oncogene. 2005 Aug 25;24(36):5561-75 [15897879.001]
  • [Cites] Mol Ther. 2000 Nov;2(5):458-69 [11082319.001]
  • [Cites] J Immunol. 2001 Feb 15;166(4):2209-17 [11160274.001]
  • [Cites] Stem Cells. 2001;19(2):118-24 [11239166.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Jan 16;98(2):609-14 [11149941.001]
  • [Cites] Ann N Y Acad Sci. 2000;917:724-31 [11268400.001]
  • [Cites] Leuk Lymphoma. 2000 Oct;39(3-4):241-56 [11342305.001]
  • [Cites] J Exp Med. 2001 Jun 18;193(12):1431-7 [11413198.001]
  • [Cites] J Exp Med. 2001 Jul 2;194(1):99-106 [11435476.001]
  • [Cites] Nature. 2001 Sep 6;413(6851):86-91 [11544531.001]
  • [Cites] J Immunol. 2002 Mar 1;168(5):2325-31 [11859122.001]
  • [Cites] Curr Opin Immunol. 2002 Apr;14(2):200-6 [11869893.001]
  • [Cites] Oncogene. 2002 May 13;21(21):3475-95 [12032783.001]
  • [Cites] Cancer Cell. 2002 Feb;1(1):75-87 [12086890.001]
  • [Cites] J Immunol. 2002 Sep 15;169(6):3021-9 [12218117.001]
  • [Cites] Stem Cells. 2002;20(5):364-79 [12351808.001]
  • [Cites] Blood. 2002 Nov 15;100(10):3828-31 [12393673.001]
  • [Cites] Nat Rev Immunol. 2002 Nov;2(11):888-97 [12415312.001]
  • [Cites] J Biol Chem. 2002 Nov 29;277(48):46289-97 [12228235.001]
  • [Cites] Trends Immunol. 2003 Apr;24(4):197-206 [12697452.001]
  • [Cites] Leukemia. 2003 May;17(5):887-93 [12750702.001]
  • [Cites] Blood. 2003 Jun 15;101(12):4966-74 [12586625.001]
  • [Cites] Leukemia. 2003 Sep;17(9):1851-7 [12970786.001]
  • [Cites] Cancer Cell. 2003 Oct;4(4):311-9 [14585358.001]
  • [Cites] Blood. 2004 Mar 1;103(5):1909-11 [14604958.001]
  • [Cites] Lancet. 2004 Feb 14;363(9408):535-6 [14975618.001]
  • [Cites] N Engl J Med. 2004 Apr 8;350(15):1535-48 [15071128.001]
  • [Cites] J Immunol. 2004 May 1;172(9):5230-9 [15100261.001]
  • [Cites] J Exp Med. 2004 Sep 6;200(5):659-69 [15353558.001]
  • [Cites] Nat Genet. 2004 Oct;36(10):1084-9 [15361874.001]
  • [Cites] Science. 2004 Oct 8;306(5694):269-71 [15472075.001]
  • [Cites] Methods Mol Med. 2005;105:311-22 [15492404.001]
  • [Cites] Science. 1991 Jul 5;253(5015):79-82 [1676542.001]
  • [Cites] Semin Immunol. 1990 Jan;2(1):51-8 [2129901.001]
  • [Cites] EMBO J. 1991 Oct;10(10):2905-10 [1717256.001]
  • [Cites] Proc Natl Acad Sci U S A. 1991 Oct 15;88(20):8900-4 [1681546.001]
  • [Cites] Blood. 1991 Dec 1;78(11):2996-3003 [1683261.001]
  • [Cites] Cell. 1991 Nov 29;67(5):889-99 [1959134.001]
  • [Cites] J Immunol. 1993 May 15;150(10):4244-52 [8387091.001]
  • [Cites] Proc Natl Acad Sci U S A. 1993 May 15;90(10):4431-5 [8099440.001]
  • [Cites] J Immunol. 1993 Jul 1;151(1):83-91 [8326141.001]
  • [Cites] J Immunol. 1993 Sep 1;151(5):2546-54 [8360476.001]
  • [Cites] Oncogene. 1994 Jan;9(1):1-12 [7905617.001]
  • [Cites] Immunology. 1994 Jan;81(1):115-9 [8132207.001]
  • [Cites] J Immunol Methods. 1994 Apr 15;170(2):145-57 [8157993.001]
  • [Cites] Blood. 1994 Sep 1;84(5):1587-93 [7520780.001]
  • [Cites] J Exp Med. 1994 Nov 1;180(5):1955-60 [7964471.001]
  • [Cites] Nature. 1995 Mar 2;374(6517):70-4 [7870176.001]
  • [Cites] Immunity. 1994 Jul;1(4):261-7 [7889413.001]
  • (PMID = 16398656.001).
  • [ISSN] 0007-1048
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] ENG
  • [Grant] United States / NHLBI NIH HHS / HL / R01HL65519; United States / NHLBI NIH HHS / HL / R01 HL066305-05; United States / NCRR NIH HHS / RR / R24RR16209; United States / NHLBI NIH HHS / HL / R01 HL065519; United States / NHLBI NIH HHS / HL / R01 HL066305; United States / NCRR NIH HHS / RR / R24 RR016209; United States / NHLBI NIH HHS / HL / HL066305-05; United States / NHLBI NIH HHS / HL / R01HL66305
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Homeodomain Proteins; 0 / Proto-Oncogene Proteins; 143275-75-6 / TLX1 protein, human
  • [Other-IDs] NLM/ NIHMS51706; NLM/ PMC2431114
  •  go-up   go-down


43. Chaidos A, Kanfer E, Apperley JF: Risk assessment in haemotopoietic stem cell transplantation: disease and disease stage. Best Pract Res Clin Haematol; 2007 Jun;20(2):125-54
Hazardous Substances Data Bank. IMATINIB MESYLATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Risk assessment in haemotopoietic stem cell transplantation: disease and disease stage.
  • [MeSH-minor] Acute Disease. Adult. Benzamides. Female. Humans. Imatinib Mesylate. Leukemia, Lymphocytic, Chronic, B-Cell / therapy. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / therapy. Leukemia, Myeloid / therapy. Male. Multiple Myeloma / therapy. Myelodysplastic Syndromes / therapy. Neoplasm Staging. Piperazines / therapeutic use. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy. Prognosis. Pyrimidines / therapeutic use. Recurrence. Risk Assessment. Survival Analysis. Transplantation, Homologous

  • Genetic Alliance. consumer health - Transplantation.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17448953.001).
  • [ISSN] 1521-6926
  • [Journal-full-title] Best practice & research. Clinical haematology
  • [ISO-abbreviation] Best Pract Res Clin Haematol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Benzamides; 0 / Piperazines; 0 / Pyrimidines; 8A1O1M485B / Imatinib Mesylate
  • [Number-of-references] 154
  •  go-up   go-down


44. Frassoni F, Gualandi F, Podestà M, Raiola AM, Ibatici A, Piaggio G, Sessarego M, Sessarego N, Gobbi M, Sacchi N, Labopin M, Bacigalupo A: Direct intrabone transplant of unrelated cord-blood cells in acute leukaemia: a phase I/II study. Lancet Oncol; 2008 Sep;9(9):831-9
Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Cord-blood transplants are associated with delayed or failed engraftment in about 20% of adult patients.
  • METHODS: Adult patients with acute leukaemia, for whom an unrelated stem-cell transplantation was indicated and no suitable unrelated human leucocyte antigen (HLA)-matched donor had been identified, were included in the study and underwent a cord-blood transplant in San Martino Hospital, Genoa, Italy.
  • Eight patients were in first complete remission, ten in second complete remission, and 14 had advanced-stage, refractory disease.
  • FINDINGS: Between March 31, 2006, and Jan 25, 2008, 32 consecutive patients with acute myeloid leukaemia (n=20) or acute lymphoblastic leukaemia (n=12) underwent a cord-blood transplant (median age 36 years [range 18-66]).
  • Four patients with advanced-stage disease died within 12 days of the procedure.
  • INTERPRETATION: Our preliminary data suggest that direct intrabone cord-blood transplantation overcomes the problem of graft failure even when low numbers of HLA-mismatched cord-blood cells are transplanted, thus leading to the possibility of use of this technique in a large number of adult patients.
  • [MeSH-major] Cord Blood Stem Cell Transplantation / methods. Leukemia, Myeloid, Acute / therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Humans. Infusions, Intraosseous. Middle Aged. Transplantation, Homologous. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Lancet Oncol. 2008 Sep;9(9):812-4 [18760236.001]
  • (PMID = 18693069.001).
  • [ISSN] 1474-5488
  • [Journal-full-title] The Lancet. Oncology
  • [ISO-abbreviation] Lancet Oncol.
  • [Language] eng
  • [Databank-accession-numbers] ClinicalTrials.gov/ NCT00696046
  • [Publication-type] Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


45. Estes DA, Lovato DM, Khawaja HM, Winter SS, Larson RS: Genetic alterations determine chemotherapy resistance in childhood T-ALL: modelling in stage-specific cell lines and correlation with diagnostic patient samples. Br J Haematol; 2007 Oct;139(1):20-30
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genetic alterations determine chemotherapy resistance in childhood T-ALL: modelling in stage-specific cell lines and correlation with diagnostic patient samples.
  • Acquired drug resistance eventually leads to treatment failure in T-cell acute lymphoblastic leukaemia (T-ALL).
  • [MeSH-major] Cell Line, Tumor. Drug Resistance, Neoplasm / genetics. Gene Expression Regulation, Leukemic. Genes, MDR. Leukemia-Lymphoma, Adult T-Cell / genetics

  • Hazardous Substances Data Bank. DAUNORUBICIN .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17854304.001).
  • [ISSN] 0007-1048
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / 1 R01 CA114589; United States / NCI NIH HHS / CA / U10 CA98543-03-14305
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / P-Glycoprotein; 0 / RNA, Small Interfering; 5J49Q6B70F / Vincristine; 9PHQ9Y1OLM / Prednisolone; EC 3.5.1.1 / Asparaginase; EC 6.3.1.1 / Aspartate-Ammonia Ligase; EC 6.3.4.5 / Argininosuccinate Synthase; ZS7284E0ZP / Daunorubicin
  •  go-up   go-down


46. Maha A, Gan GG, Koh CL: Phenotype and TCR-gamma gene rearrangements in a Malaysian cohort of T-cell leukaemia/lymphoma cases. Hematology; 2010 Dec;15(6):382-90

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phenotype and TCR-gamma gene rearrangements in a Malaysian cohort of T-cell leukaemia/lymphoma cases.
  • HLA-DR has been reported to be expressed in immature T-cell acute lymphoblastic leukemia (ALL) and also confer a poorer treatment outcome.
  • We also observed a higher incidence of mediastinal mass (67%) in the HLA-DR-subgroup in the Pre-T stage.
  • [MeSH-major] Gene Rearrangement, T-Lymphocyte. Leukemia-Lymphoma, Adult T-Cell / pathology. Receptors, Antigen, T-Cell, gamma-delta / genetics
  • [MeSH-minor] Adolescent. Adult. Aged. Antigens, CD / analysis. Biomarkers. Cell Differentiation. Child. Child, Preschool. Female. Genes, T-Cell Receptor / genetics. HLA-DR Antigens. Humans. Leukemia, T-Cell / classification. Leukemia, T-Cell / genetics. Leukemia, T-Cell / pathology. Malaysia. Male. Middle Aged. Phenotype. Prognosis. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21114900.001).
  • [ISSN] 1607-8454
  • [Journal-full-title] Hematology (Amsterdam, Netherlands)
  • [ISO-abbreviation] Hematology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Biomarkers; 0 / HLA-DR Antigens; 0 / Receptors, Antigen, T-Cell, gamma-delta
  •  go-up   go-down


47. Krawczuk-Rybak M, Solarz E, Wysocka J, Wojtkowska M, Matysiak M, Gadomski A, Kazanowska B, Sega-Pondel D: [Testicular function in young men treated in prepubertal period for childhood malignancy]. Pediatr Endocrinol Diabetes Metab; 2008;14(2):93-8
Hazardous Substances Data Bank. MENOTROPINS .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • MATERIAL AND METHODS: In thirty-two pubertal and postpubertal male survivors of childhood cancer (acute lymphoblastic leukemia, ALL - 14, non-Hodgkin lymphoma, NHL - 6, Hodgkin lymphoma, HL and solid tumors - 4) testicular volume and serum FSH, LH, testosterone, inhibin B and calculated quotient inhibin B:FSH were measured.
  • Controls were 15 healthy boys matched by age and Tanner stage.
  • [MeSH-minor] Adolescent. Adult. Antineoplastic Combined Chemotherapy Protocols / adverse effects. Biomarkers / metabolism. Child. Follicle Stimulating Hormone / metabolism. Humans. Male. Puberty / metabolism. Quality of Life. Radiotherapy, Adjuvant / adverse effects. Spermatogenesis / drug effects. Spermatogenesis / radiation effects. Survivors

  • MedlinePlus Health Information. consumer health - Cancer in Children.
  • MedlinePlus Health Information. consumer health - Testicular Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18721495.001).
  • [ISSN] 2081-237X
  • [Journal-full-title] Pediatric endocrinology, diabetes, and metabolism
  • [ISO-abbreviation] Pediatr Endocrinol Diabetes Metab
  • [Language] pol
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Biomarkers; 0 / inhibin B; 57285-09-3 / Inhibins; 9002-68-0 / Follicle Stimulating Hormone
  •  go-up   go-down


48. Chauhan A, Weiss J, Warrier R: Effective management of pain in pediatric hematology and oncology. Asian Pac J Cancer Prev; 2010;11(2):577-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • 5 year survival of children with acute lymphoblastic leukemia has increased from 25% to 80%.
  • Bone pain is also a prominent symptom in late stage neuroblastoma, and of course in bone tumors.
  • [MeSH-major] Hodgkin Disease / complications. Kidney Neoplasms / complications. Lymphoma, Non-Hodgkin / complications. Pain / drug therapy. Pain / etiology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / complications. Wilms Tumor / complications
  • [MeSH-minor] Adult. Humans

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • MedlinePlus Health Information. consumer health - Pain.
  • MedlinePlus Health Information. consumer health - Wilms Tumor.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20843157.001).
  • [ISSN] 2476-762X
  • [Journal-full-title] Asian Pacific journal of cancer prevention : APJCP
  • [ISO-abbreviation] Asian Pac. J. Cancer Prev.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Thailand
  •  go-up   go-down


49. Merkle M, Rupprecht HD: [Lymphoproliferative disease following kidney transplantation]. Dtsch Med Wochenschr; 2005 Jul 15;130(28-29):1691-4
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Bacterial or viral enteritis could be excluded as well as a mucosa-associated lymphatic tissue lymphoma (MALT-lymphoma).
  • Histology showed an EBV-negative, highly aggressive B-blastic lymphoma.
  • TREATMENT AND COURSE: Because of the advanced lymphoma stage immunosuppressive therapy was reduced and immunochemotherapy according to the CHOP-protocol (cyclophosphamide, doxorubicin, vincristine, prednisone) in combination with rituximab (R-CHOP) was started.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cyclophosphamide / therapeutic use. Doxorubicin / therapeutic use. Kidney Transplantation / adverse effects. Lymphoma, B-Cell / etiology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / etiology. Prednisone / therapeutic use. Vincristine / therapeutic use
  • [MeSH-minor] Abdominal Pain. Adult. Diagnosis, Differential. Diarrhea. Humans. Immunosuppressive Agents / administration & dosage. Immunosuppressive Agents / adverse effects. Male. Remission Induction. Risk Factors

  • Genetic Alliance. consumer health - Kidney Disease.
  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Kidney Transplantation.
  • MedlinePlus Health Information. consumer health - Steroids.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16003604.001).
  • [ISSN] 0012-0472
  • [Journal-full-title] Deutsche medizinische Wochenschrift (1946)
  • [ISO-abbreviation] Dtsch. Med. Wochenschr.
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Immunosuppressive Agents; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


50. Kunsdorf-Wnuk A, Marzec-Lewenstein E, Arct-Danielak D, Musioł E, Bohatyrewicz R, Becht R: The use of recombinant human activated protein C (rhAPC) in the treatment of severe sepsis in immunosuppressed patients in the course of hematological diseases. Med Sci Monit; 2005 Aug;11(8):CS49-55
MedlinePlus Health Information. consumer health - Sepsis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We present two cases of treating severe sepsis utilizing recombinant human activated protein C (rhAPC) in the course of bilateral pneumonia in patients with hairy cell leukemia (HCL) and T-cell acute lymphoblastic leukemia (ALL).
  • Treatment outcome was uncertain because of the patients' hematological condition, so rapid restoration of respiratory efficiency and no disease progression after discontinuing treatment was a great success, possibly due to implementing Xigris at a relatively early stage of sepsis and the intensive therapy conducted according to Surviving Sepsis Campaign guidelines.
  • [MeSH-major] Immune Tolerance. Leukemia, Hairy Cell / complications. Precursor Cell Lymphoblastic Leukemia-Lymphoma / complications. Protein C / therapeutic use. Sepsis / complications. Sepsis / drug therapy
  • [MeSH-minor] Adult. Enzyme Activation. Humans. Male. Recombinant Proteins / therapeutic use

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16049385.001).
  • [ISSN] 1234-1010
  • [Journal-full-title] Medical science monitor : international medical journal of experimental and clinical research
  • [ISO-abbreviation] Med. Sci. Monit.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Protein C; 0 / Recombinant Proteins
  •  go-up   go-down


51. Bolarinwa RA, Ndakotsu MA, Oyekunle AA, Salawu L, Akinola NO, Durosinmi MA: AIDS-related lymphomas in Nigeria. Braz J Infect Dis; 2009 Oct;13(5):359-61
Genetic Alliance. consumer health - AIDS-HIV.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Aggressive non-Hodgkin's lymphoma (NHL), including primary central nervous system (CNS) lymphoma, lymphoblastic lymphoma and non-endemic Burkitt's lymphoma have been recognized as AIDS-defining cancers in most developed countries.
  • Patients with a histological diagnosis of malignant chronic lymphoproliferative diseases {non-Hodgkin lymphoma (NHL), chronic lymphocytic leukaemia (CLL), Burkitt's lymphoma (BL) and Hodgkin lymphoma (HL)} at the Obafemi Awolowo University Teaching Hospitals' Complex, Ile-Ife from January 1993 to August 2008 were noted.
  • A total of 391 patients were histologically confirmed to have lymphoma {NHL-109, (27.9%); CLL-76, (19.4%); BL-178, (45.5%) and HL-28, (7.2%)} during the study period.
  • Patients with NHL presented at advanced stage of the disease (at least clinical stage IIIb), and all those with CLL presented at stage C of the International Working Party Classification.
  • However, it is interesting that no single case of AIDS-associated BL was seen, despite the fact that Burkitt's lymphoma is endemic in this part of the world.
  • All the patients presented at a very advanced stage of the disease with significantly shortened survival.
  • [MeSH-major] Lymphoma, AIDS-Related / epidemiology
  • [MeSH-minor] Adult. Female. Humans. Incidence. Male. Middle Aged. Nigeria / epidemiology. Prevalence. Retrospective Studies. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20428636.001).
  • [ISSN] 1678-4391
  • [Journal-full-title] The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases
  • [ISO-abbreviation] Braz J Infect Dis
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Brazil
  •  go-up   go-down


52. Styczynski J, Wysocki M, Debski R, Czyzewski K, Balwierz W, Juraszewska E, Matysiak M, Malinowska I, Stanczak E, Sońta-Jakimczyk D, Szczepanski T, Wachowiak J, Konatkowska B, Balcerska A, Ploszynska A, Kowalczyk J, Stefaniak J, Badowska W, Wieczorek M, Olejnik I, Krawczuk-Rybak M, Kuzmicz M: In vitro sensitivity of leukemic cells to nucleoside derivatives in childhood acute leukemias: good activity in leukemic relapses. Neoplasma; 2005;52(1):74-8
Hazardous Substances Data Bank. VIDARABINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The objective of the study was the analysis of in vitro cellular drug sensitivity in childhood acute lymphoblastic (ALL) and myeloid (AML) leukemia.
  • In summary, tested nucleoside analogues presented relatively good activity against childhood leukemias at relapse stage.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Cladribine / pharmacology. Cytarabine / pharmacology. Leukemia, Myeloid / pathology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology. Vidarabine / analogs & derivatives. Vidarabine / pharmacology
  • [MeSH-minor] Adolescent. Adult. Cell Death. Child. Child, Preschool. Dose-Response Relationship, Drug. Drug Resistance, Neoplasm. Drug Screening Assays, Antitumor. Female. Humans. Infant. Infant, Newborn. Male. Recurrence. Tumor Cells, Cultured

  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. FLUDARABINE .
  • Hazardous Substances Data Bank. CLADRIBINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15739031.001).
  • [ISSN] 0028-2685
  • [Journal-full-title] Neoplasma
  • [ISO-abbreviation] Neoplasma
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Slovakia
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 04079A1RDZ / Cytarabine; 47M74X9YT5 / Cladribine; FA2DM6879K / Vidarabine; P2K93U8740 / fludarabine
  •  go-up   go-down


53. Ostrowska H, Hempel D, Holub M, Sokolowski J, Kloczko J: Assessment of circulating proteasome chymotrypsin-like activity in plasma of patients with acute and chronic leukemias. Clin Biochem; 2008 Nov;41(16-17):1377-83
Hazardous Substances Data Bank. CHYMOTRYPSIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: We evaluated whether the proteasomal chymotrypsin-like (ChT-L) activity is increased in plasma of patients with acute lymphoblastic (ALL), acute myeloblastic (AML) and chronic lymphocytic (CLL) leukemias.
  • CONCLUSIONS: Plasma proteasome ChT-L activity can be a useful bio-marker for patients with acute leukemia at the blast stage.
  • [MeSH-minor] Adolescent. Adult. Aged. Case-Control Studies. Female. Humans. Hydrolysis / drug effects. L-Lactate Dehydrogenase / blood. Leukemia, Lymphocytic, Chronic, B-Cell / blood. Leukemia, Lymphocytic, Chronic, B-Cell / diagnosis. Leukemia, Myeloid, Acute / blood. Leukemia, Myeloid, Acute / diagnosis. Male. Middle Aged. Oligopeptides / pharmacology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / blood. Precursor Cell Lymphoblastic Leukemia-Lymphoma / diagnosis. Proteasome Inhibitors. Protein Subunits / metabolism. Sodium Dodecyl Sulfate / pharmacology

  • MedlinePlus Health Information. consumer health - Childhood Leukemia.
  • MedlinePlus Health Information. consumer health - Leukemia.
  • Hazardous Substances Data Bank. SODIUM LAURYL SULFATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18773885.001).
  • [ISSN] 1873-2933
  • [Journal-full-title] Clinical biochemistry
  • [ISO-abbreviation] Clin. Biochem.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Oligopeptides; 0 / Proteasome Inhibitors; 0 / Protein Subunits; 134381-21-8 / epoxomicin; 368GB5141J / Sodium Dodecyl Sulfate; EC 1.1.1.27 / L-Lactate Dehydrogenase; EC 3.4.21.1 / Chymotrypsin; EC 3.4.25.1 / Proteasome Endopeptidase Complex
  •  go-up   go-down


54. Armand P, Kim HT, Cutler CS, Ho VT, Koreth J, Ritz J, Alyea EP, Antin JH, Soiffer RJ: A prognostic score for patients with acute leukemia or myelodysplastic syndromes undergoing allogeneic stem cell transplantation. Biol Blood Marrow Transplant; 2008 Jan;14(1):28-35
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We propose a simple scoring system for patients with acute myelogenous leukemia (AML), acute lymphoblastic leukemia (ALL), or MDS, based on a retrospective analysis of 445 patients undergoing SCT at our institution (divided into training and validation subsets).
  • The score depends on 5 variables: age, disease, stage at transplantation, cytogenetics, and pretransplantation ferritin.

  • Genetic Alliance. consumer health - Myelodysplastic syndromes.
  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • MedlinePlus Health Information. consumer health - Myelodysplastic Syndromes.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 2000 Feb 15;95(4):1188-94 [10666189.001]
  • [Cites] Biol Blood Marrow Transplant. 2007 Jun;13(6):655-64 [17531775.001]
  • [Cites] Int J Hematol. 2002 Aug;76 Suppl 2:29-34 [12430896.001]
  • [Cites] Cancer Treat Rev. 2003 Feb;29(1):3-10 [12633575.001]
  • [Cites] Bone Marrow Transplant. 2004 Mar;33(5):477-82 [14730333.001]
  • [Cites] Int J Hematol. 2004 Jun;79(5):495-500 [15239403.001]
  • [Cites] Stat Med. 1984 Apr-Jun;3(2):143-52 [6463451.001]
  • [Cites] JAMA. 1993 Jul 7;270(1):57-60 [8510297.001]
  • [Cites] N Engl J Med. 1993 Sep 30;329(14):987-94 [8141877.001]
  • [Cites] Bone Marrow Transplant. 1995 Aug;16(2):203-8 [7581137.001]
  • [Cites] Blood. 1996 Jan 1;87(1):51-8 [8547676.001]
  • [Cites] Blood. 1997 Mar 15;89(6):2079-88 [9058730.001]
  • [Cites] Leukemia. 1997 Mar;11(3):416-9 [9067582.001]
  • [Cites] Blood. 1997 Oct 15;90(8):2931-8 [9376573.001]
  • [Cites] Blood. 1998 Sep 15;92(6):1910-7 [9731047.001]
  • [Cites] Blood. 1998 Oct 1;92(7):2322-33 [9746770.001]
  • [Cites] Leukemia. 1998 Sep;12 Suppl 1:S25-9 [9777891.001]
  • [Cites] Lancet. 1998 Oct 3;352(9134):1087-92 [9798583.001]
  • [Cites] Ann Hematol. 2005 Jan;84(1):25-32 [15349754.001]
  • [Cites] Blood. 2005 Oct 15;106(8):2912-9 [15994282.001]
  • [Cites] Hematology Am Soc Hematol Educ Program. 2005;:151-5 [16304373.001]
  • [Cites] Hematology Am Soc Hematol Educ Program. 2005;:167-73 [16304376.001]
  • [Cites] Ann Intern Med. 2006 Mar 21;144(6):407-14 [16549853.001]
  • [Cites] Biol Blood Marrow Transplant. 2006 Sep;12(9):954-64 [16920562.001]
  • [Cites] Blood. 2007 Jan 15;109(2):431-48 [16960150.001]
  • [Cites] Acta Med Port. 2006 Sep-Oct;19(5):343-7 [17376319.001]
  • [Cites] Blood. 2007 Apr 15;109(8):3189-97 [17170120.001]
  • [Cites] Blood. 2007 May 15;109(10):4586-8 [17234738.001]
  • [Cites] Bone Marrow Transplant. 2002 Jun;29(12):987-9 [12098067.001]
  • (PMID = 18158958.001).
  • [ISSN] 1523-6536
  • [Journal-full-title] Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
  • [ISO-abbreviation] Biol. Blood Marrow Transplant.
  • [Language] ENG
  • [Grant] United States / NHLBI NIH HHS / HL / HL070149-050001; United States / NHLBI NIH HHS / HL / P01 HL070149; United States / NCI NIH HHS / CA / T32 CA009172; United States / NHLBI NIH HHS / HL / P01 HL070149-050001
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Validation Studies
  • [Publication-country] United States
  • [Chemical-registry-number] 9007-73-2 / Ferritins
  • [Other-IDs] NLM/ NIHMS37119; NLM/ PMC2212610
  •  go-up   go-down


55. Li X, Gounari F, Protopopov A, Khazaie K, von Boehmer H: Oncogenesis of T-ALL and nonmalignant consequences of overexpressing intracellular NOTCH1. J Exp Med; 2008 Nov 24;205(12):2851-61
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Mutations resulting in overexpression of intracellular Notch1 (ICN1) are frequently observed in human T cell acute lymphoblastic leukemia (T-ALL).
  • The first tumorigenic cells are detected among more immature CD4(-)8(+)TCR-alphabeta(-) cells that give rise to monoclonal tumors with a single, unique TCR-beta chain and diverse TCR-alpha chains, pinpointing malignant transformation to a stage after pre-TCR signaling and before completion of TCR-alpha rearrangement.

  • MedlinePlus Health Information. consumer health - Stem Cells.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nature. 2007 Jun 21;447(7147):966-71 [17515920.001]
  • [Cites] Nature. 1985 Mar 7-13;314(6006):103-7 [2983227.001]
  • [Cites] J Exp Med. 2007 Aug 6;204(8):1813-24 [17646409.001]
  • [Cites] Cell. 2007 Jun 1;129(5):879-90 [17540169.001]
  • [Cites] Genes Dev. 1999 Oct 15;13(20):2658-69 [10541552.001]
  • [Cites] Genes Dev. 1999 Oct 15;13(20):2678-90 [10541554.001]
  • [Cites] Blood. 2000 Mar 15;95(6):2104-10 [10706881.001]
  • [Cites] Immunity. 2001 Jan;14(1):45-55 [11163229.001]
  • [Cites] Nat Immunol. 2001 Mar;2(3):235-41 [11224523.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Mar 19;99(6):3788-93 [11891328.001]
  • [Cites] Nat Immunol. 2002 May;3(5):483-8 [11927911.001]
  • [Cites] Nature. 1985 May 16-22;315(6016):232-3 [3873615.001]
  • [Cites] Cell. 1991 Aug 9;66(3):533-40 [1868548.001]
  • [Cites] Nature. 1995 Jun 29;375(6534):795-8 [7596413.001]
  • [Cites] Genes Dev. 1996 Aug 1;10(15):1930-44 [8756350.001]
  • [Cites] Annu Rev Immunol. 1997;15:433-52 [9143695.001]
  • [Cites] Mol Cell Biol. 1997 Aug;17(8):4782-91 [9234734.001]
  • [Cites] Science. 1999 Apr 30;284(5415):770-6 [10221902.001]
  • [Cites] Mol Cell. 1999 Aug;4(2):199-207 [10488335.001]
  • [Cites] Curr Opin Hematol. 2004 Nov;11(6):426-33 [15548998.001]
  • [Cites] Nat Rev Immunol. 2005 Jun;5(6):497-508 [15928681.001]
  • [Cites] Nat Rev Mol Cell Biol. 2005 Aug;6(8):635-45 [16064138.001]
  • [Cites] Nat Immunol. 2005 Sep;6(9):881-8 [16056227.001]
  • [Cites] J Exp Med. 2006 May 15;203(5):1329-42 [16682500.001]
  • [Cites] Blood. 2006 Jul 1;108(1):305-10 [16507772.001]
  • [Cites] Genes Dev. 2006 Aug 1;20(15):2096-109 [16847353.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Nov 28;103(48):18261-6 [17114293.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Apr 30;99(9):6274-9 [11983916.001]
  • [Cites] Cancer Cell. 2002 Feb;1(1):75-87 [12086890.001]
  • [Cites] Cancer Cell. 2002 Mar;1(2):133-43 [12086872.001]
  • [Cites] Cell. 2002 Jun 28;109(7):811-21 [12110179.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Aug 20;99(17):11322-7 [12172006.001]
  • [Cites] Mol Cell Biol. 2003 Jan;23(2):655-64 [12509463.001]
  • [Cites] Blood. 2003 Apr 1;101(7):2797-803 [12517816.001]
  • [Cites] EMBO J. 2003 Nov 3;22(21):5780-92 [14592976.001]
  • [Cites] EMBO Rep. 2003 Nov;4(11):1067-72 [14566327.001]
  • [Cites] Cancer Cell. 2003 Dec;4(6):451-61 [14706337.001]
  • [Cites] Blood. 2004 Sep 15;104(6):1696-702 [15187027.001]
  • [Cites] Science. 2004 Oct 8;306(5694):269-71 [15472075.001]
  • [Cites] J Exp Med. 2007 Aug 6;204(8):1825-35 [17646408.001]
  • (PMID = 18981238.001).
  • [ISSN] 1540-9538
  • [Journal-full-title] The Journal of experimental medicine
  • [ISO-abbreviation] J. Exp. Med.
  • [Language] ENG
  • [Databank-accession-numbers] GEO/ GSE12948
  • [Grant] United States / NIAID NIH HHS / AI / R01 AI045846; United States / NCI NIH HHS / CA / P01 CA109901; United States / NCI NIH HHS / CA / T32 CA070083; United States / NCI NIH HHS / CA / T32-CA70083; United States / NIAID NIH HHS / AI / R01 AI45846; United States / NCI NIH HHS / CA / CA109901
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Notch1 protein, mouse; 0 / Proto-Oncogene Proteins c-myc; 0 / Receptor, Notch1; 0 / Receptors, Antigen, T-Cell, alpha-beta; 0 / Tumor Suppressor Protein p53
  • [Other-IDs] NLM/ PMC2585834
  •  go-up   go-down


56. Aversa F: Haploidentical haematopoietic stem cell transplantation for acute leukaemia in adults: experience in Europe and the United States. Bone Marrow Transplant; 2008 Mar;41(5):473-81
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Improvements will come with successful implementation of strategies to accelerate and strengthen post transplant immune reconstitution as well as transplantation of patients in early stage disease.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation / methods. Leukemia, Myeloid, Acute / therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy
  • [MeSH-minor] Adult. Disease-Free Survival. Europe. Graft vs Host Disease / prevention & control. Haploidy. Humans. Transplantation Conditioning / adverse effects. Transplantation Conditioning / methods. Transplantation, Homologous / adverse effects. Transplantation, Homologous / methods. United States

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18176612.001).
  • [ISSN] 0268-3369
  • [Journal-full-title] Bone marrow transplantation
  • [ISO-abbreviation] Bone Marrow Transplant.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 82
  •  go-up   go-down


57. Babusikova O, Stevulova L, Fajtova M: Immunophenotyping parameters as prognostic factors in T-acute leukemia patients. Neoplasma; 2009;56(6):508-13
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The main aim was concerned to more proper T-ALL diagnosis and stage definition and identification of the prognostic factors and the useful markers for the follow-up of T-ALL in remission.
  • New knowledge of the T-cell maturation stages of hematopoietic cells in bone marrow and thymus has been applied, as each T-acute leukemia clone is representative of one blocked stage through maturation.
  • Patients with more favorable prognosis (i. e. those of cortical stage) could have been already differentiated at diagnosis from those, allocated to pro-T stage, with very immature phenotypes and of an unfavorable clinical course.
  • [MeSH-major] Antigens, CD / immunology. Antigens, Differentiation, T-Lymphocyte / immunology. Biomarkers, Tumor / immunology. HLA-DR Antigens / analysis. Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / immunology
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Female. Flow Cytometry. Humans. Immunophenotyping. Male. Middle Aged. Neoplasm, Residual / immunology. Phenotype. Prognosis. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19728759.001).
  • [ISSN] 0028-2685
  • [Journal-full-title] Neoplasma
  • [ISO-abbreviation] Neoplasma
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Slovakia
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, Differentiation, T-Lymphocyte; 0 / Biomarkers, Tumor; 0 / HLA-DR Antigens
  •  go-up   go-down


58. Saxena A, Rai A, Raina V, Seth T, Mitra DK: Expression of CD13/aminopeptidase N in precursor B-cell leukemia: role in growth regulation of B cells. Cancer Immunol Immunother; 2010 Jan;59(1):125-35
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of CD13/aminopeptidase N in precursor B-cell leukemia: role in growth regulation of B cells.
  • Here, we attempted to study the stage specific expression of CD13 on ALL-B blasts and understand its role in leukemogenesis as pertaining to stage of B-cell ontogeny.
  • This strongly indicates leukemogenesis at an early stage of B-cell development.
  • We hypothesized that neoplastic transformation at this stage may be facilitated by CD13.
  • CD13 may thus be an important target for novel molecular therapy of early stage acute B-cell leukemia.
  • [MeSH-major] Antigens, CD13 / immunology. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / immunology. Precursor Cells, B-Lymphoid / immunology
  • [MeSH-minor] Adolescent. Adult. Aged. Cell Proliferation. Child. Child, Preschool. Female. Humans. Male. Middle Aged. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19562339.001).
  • [ISSN] 1432-0851
  • [Journal-full-title] Cancer immunology, immunotherapy : CII
  • [ISO-abbreviation] Cancer Immunol. Immunother.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] EC 3.4.11.2 / Antigens, CD13
  •  go-up   go-down


59. Köhler K, Regner A, Koenigsmann M, Franke A, Frommer J: [Illness perceptions of patients suffering from acute leukaemia one week after diagnosis]. Z Psychosom Med Psychother; 2005;51(4):388-402
MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVES: To investigate illness perceptions, treatment expectations, and treatment experiences of patients suffering from acute leukaemia in the initial stage of their disease.
  • [MeSH-major] Leukemia, Myeloid, Acute / psychology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / psychology. Sick Role
  • [MeSH-minor] Activities of Daily Living / classification. Activities of Daily Living / psychology. Adaptation, Psychological. Adult. Aged. Defense Mechanisms. Female. Humans. Interview, Psychological. Male. Middle Aged. Personality Assessment. Prognosis. Risk Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16402336.001).
  • [ISSN] 1438-3608
  • [Journal-full-title] Zeitschrift für Psychosomatische Medizin und Psychotherapie
  • [ISO-abbreviation] Z Psychosom Med Psychother
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


60. Babusíková O, Zelezníková T, Kirschnerová G, Kankuri E: Hematogones in acute leukemia during and after therapy. Leuk Lymphoma; 2008 Oct;49(10):1935-44
MedlinePlus Health Information. consumer health - Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Stage 3 hematogones were found usually in children and were thus frequent in B-ALL.
  • [MeSH-minor] Acute Disease. Adolescent. Adult. Aged. Aged, 80 and over. Bone Marrow Examination. Child. Child, Preschool. Flow Cytometry. Humans. Immunophenotyping. Infant. Infant, Newborn. Middle Aged. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / immunology. Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / immunology

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • MedlinePlus Health Information. consumer health - Childhood Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Leuk Lymphoma. 2009 Apr;50(4):523-4 [19373647.001]
  • (PMID = 18452085.001).
  • [ISSN] 1029-2403
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


61. Horowitz N, Brenner B: Thrombophilia and cancer. Pathophysiol Haemost Thromb; 2008;36(3-4):131-6
MedlinePlus Health Information. consumer health - Cancer in Children.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Most studies are small, and results are varied by geography, tumor type, stage of disease and therapy.
  • [MeSH-minor] Activated Protein C Resistance / complications. Activated Protein C Resistance / genetics. Adult. Antibodies, Antiphospholipid / blood. Antineoplastic Agents / adverse effects. Antineoplastic Agents / therapeutic use. Antineoplastic Agents, Hormonal / adverse effects. Antineoplastic Agents, Hormonal / therapeutic use. Asparaginase / adverse effects. Asparaginase / therapeutic use. Catheterization, Central Venous / adverse effects. Child. Factor V / genetics. Female. Genotype. Humans. Hyperhomocysteinemia / blood. Hyperhomocysteinemia / complications. Male. Methylenetetrahydrofolate Reductase (NADPH2) / genetics. Middle Aged. Precursor Cell Lymphoblastic Leukemia-Lymphoma / blood. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Prothrombin / genetics. Risk Factors. Thrombosis / etiology. Thrombosis / physiopathology. Thrombosis / prevention & control

  • Genetic Alliance. consumer health - Thrombophilia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 S. Karger AG, Basel.
  • (PMID = 19176986.001).
  • [ISSN] 1424-8840
  • [Journal-full-title] Pathophysiology of haemostasis and thrombosis
  • [ISO-abbreviation] Pathophysiol. Haemost. Thromb.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antibodies, Antiphospholipid; 0 / Antineoplastic Agents; 0 / Antineoplastic Agents, Hormonal; 0 / factor V Leiden; 9001-24-5 / Factor V; 9001-26-7 / Prothrombin; EC 1.5.1.20 / Methylenetetrahydrofolate Reductase (NADPH2); EC 3.5.1.1 / Asparaginase
  • [Number-of-references] 38
  •  go-up   go-down


62. Hara S, Yokote T, Oka S, Akioka T, Kobayashi K, Hirata Y, Miyoshi T, Tsuji M, Hanafusa T: Endophthalmitis due to Trichosporon beigelii in acute leukemia. Int J Hematol; 2007 Jun;85(5):415-7
Hazardous Substances Data Bank. FLUCONAZOLE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The administration of AMPH-B is likely to be more effective in treating endophthalmitis due to trichosporonosis when the disease is at an early stage.
  • [MeSH-major] Endophthalmitis / complications. Endophthalmitis / microbiology. Leukemia, Myeloid / complications. Mycoses / complications. Precursor Cell Lymphoblastic Leukemia-Lymphoma / complications. Trichosporon
  • [MeSH-minor] Acute Disease. Adult. Amphotericin B / administration & dosage. Antifungal Agents / administration & dosage. Drug Resistance, Fungal. Female. Fluconazole / administration & dosage. Flucytosine / administration & dosage. Humans. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Fungal Infections.
  • Hazardous Substances Data Bank. AMPHOTERICIN B .
  • Hazardous Substances Data Bank. FLUCYTOSINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Rocz Panstw Zakl Hig. 1994;45(4):337-46 [7792523.001]
  • [Cites] Medicine (Baltimore). 1986 Jul;65(4):268-79 [3523114.001]
  • [Cites] Cancer. 1975 Sep;36(3):1106-10 [52400.001]
  • [Cites] J Clin Oncol. 1991 Jul;9(7):1210-4 [2045861.001]
  • [Cites] Antimicrob Agents Chemother. 2000 Jan;44(1):57-62 [10602723.001]
  • [Cites] N Engl J Med. 1999 Mar 11;340(10):764-71 [10072411.001]
  • [Cites] Curr Top Med Mycol. 1993;5:79-113 [8242806.001]
  • [Cites] Ann Intern Med. 1985 Oct;103(4):620-5 [3862359.001]
  • [Cites] Antimicrob Agents Chemother. 2002 Jun;46(6):1857-69 [12019101.001]
  • [Cites] Ophthalmology. 1982 Feb;89(2):152-6 [6951137.001]
  • [Cites] Infect Dis Clin North Am. 1989 Mar;3(1):43-52 [2647833.001]
  • [Cites] Cancer. 1981 Nov 1;48(9):2107-11 [6945903.001]
  • [Cites] Retina. 2003 Jun;23(3):404-5 [12824845.001]
  • [Cites] Med Mycol. 2000 Feb;38(1):27-30 [10746224.001]
  • [Cites] Cancer. 1980 Jan 15;45(2):367-71 [6927961.001]
  • [Cites] Br J Ophthalmol. 1974 Jun;58(6):591-4 [4425639.001]
  • [Cites] Clin Infect Dis. 1992 Mar;14 Suppl 1:S161-9 [1314105.001]
  • [Cites] Clin Microbiol Infect. 2001;7 Suppl 2:8-24 [11525222.001]
  • [Cites] Rev Infect Dis. 1989 May-Jun;11(3):369-78 [2749101.001]
  • [Cites] Scand J Infect Dis. 1978;10(3):225-6 [715385.001]
  • [Cites] Am J Ophthalmol. 2005 Jan;139(1):135-40 [15652837.001]
  • [Cites] J Med Microbiol. 1970 Feb;3(1):191-3 [5448879.001]
  • [Cites] Blood. 2004 Sep 15;104(6):1624-30 [15178574.001]
  • [Cites] Chemotherapy. 1998 Jan-Feb;44(1):55-62 [9444410.001]
  • [Cites] Eur J Clin Chem Clin Biochem. 1997 Jul;35(7):553-60 [9263735.001]
  • [Cites] J Clin Lab Anal. 1995;9(5):334-9 [8531015.001]
  • [Cites] Clin Infect Dis. 1992 Nov;15(5):781-7 [1445976.001]
  • [Cites] Clin Infect Dis. 2003 Mar 1;36(5):630-7 [12594645.001]
  • [Cites] J Clin Microbiol. 1998 Oct;36(10 ):2950-6 [9738049.001]
  • [Cites] Mycoses. 1994 Jan-Feb;37(1-2):3-10 [7935589.001]
  • (PMID = 17562617.001).
  • [ISSN] 0925-5710
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antifungal Agents; 7XU7A7DROE / Amphotericin B; 8VZV102JFY / Fluconazole; D83282DT06 / Flucytosine
  •  go-up   go-down


63. Bergeron J, Clappier E, Radford I, Buzyn A, Millien C, Soler G, Ballerini P, Thomas X, Soulier J, Dombret H, Macintyre EA, Asnafi V: Prognostic and oncogenic relevance of TLX1/HOX11 expression level in T-ALLs. Blood; 2007 Oct 1;110(7):2324-30
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • TLX1 is a homeodomain transcription factor generally associated with a favorable outcome in T-cell acute lymphoblastic leukemia (T-ALL).
  • We have studied 264 unselected T-ALLs (171 adults and 93 children) and show that T-ALLs expressing high levels of TLX1 (n = 35, 13%), defined as a real-time quantitative polymerase chain reaction (RQ-PCR) level of TLX1 greater than 1.00 ABL, form a homogeneous oncogenic group, based on their uniform stage of maturation arrest and oncogenetic and transcriptional profiles.
  • Prognostic analysis within the adult LALA94 and GRAALL03 prospective protocols demonstrate a better event-free survival (P = .035) and a marked trend for longer overall survival (P = .059) for TLX1-high T-ALLs, while the expression of lower levels of TLX1 does not impact on prognosis.
  • [MeSH-major] Gene Expression Regulation, Neoplastic. Homeodomain Proteins / genetics. Leukemia-Lymphoma, Adult T-Cell / genetics. Leukemia-Lymphoma, Adult T-Cell / pathology. Proto-Oncogene Proteins / genetics
  • [MeSH-minor] Adolescent. Adult. Alleles. Antineoplastic Combined Chemotherapy Protocols. Chromosomes, Human, Pair 10 / genetics. Female. Genotype. Humans. Immunogenetics. Karyotyping. Male. Middle Aged. Oligonucleotide Array Sequence Analysis. Prognosis. RNA, Messenger / genetics. Survival Rate. Transcription, Genetic / genetics

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17609427.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Homeodomain Proteins; 0 / Proto-Oncogene Proteins; 0 / RNA, Messenger; 143275-75-6 / TLX1 protein, human
  •  go-up   go-down


64. Marculescu R, Vanura K, Montpellier B, Roulland S, Le T, Navarro JM, Jäger U, McBlane F, Nadel B: Recombinase, chromosomal translocations and lymphoid neoplasia: targeting mistakes and repair failures. DNA Repair (Amst); 2006 Sep 8;5(9-10):1246-58

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Due to the unique feature of lymphoid cells to somatically rearrange and mutate receptor genes, and to the corresponding strong activity of the immune enhancers/promoters at that stage of cell development, B- and T-cell differentiation pathways represent propitious targets for chromosomal translocations and oncogene activation.
  • Surprisingly, V(D)J-mediated translocations turn out to be restricted to two specific sub-types of lymphoid malignancies, T-cell acute lymphoblastic leukemias, and a restricted set of mature B-cell Non-Hodgkin's lymphomas.
  • [MeSH-major] DNA Repair. Leukemia-Lymphoma, Adult T-Cell / genetics. Lymphoma, B-Cell / genetics. Recombinases / genetics. Recombination, Genetic. Translocation, Genetic

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16798110.001).
  • [ISSN] 1568-7864
  • [Journal-full-title] DNA repair
  • [ISO-abbreviation] DNA Repair (Amst.)
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Recombinases
  • [Number-of-references] 88
  •  go-up   go-down


65. Ng AK, Kenney LB, Gilbert ES, Travis LB: Secondary malignancies across the age spectrum. Semin Radiat Oncol; 2010 Jan;20(1):67-78
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Development of a second malignancy is one of the most serious late effects in survivors of both childhood and adult-onset cancers.
  • Potential explanations for the varying risk patterns by age include differences in susceptibility of individual tissue/organ to carcinogenesis based on stage of development and level of tissue maturity, microenvironment, attained age, and lifestyle factors.
  • [MeSH-minor] Adult. Age Distribution. Aging. Breast Neoplasms / epidemiology. Breast Neoplasms / pathology. Breast Neoplasms / secondary. Child. Child, Preschool. Female. Genital Neoplasms, Male / epidemiology. Genital Neoplasms, Male / pathology. Genital Neoplasms, Male / therapy. Hodgkin Disease / epidemiology. Hodgkin Disease / pathology. Hodgkin Disease / therapy. Humans. Incidence. Life Style. Lung Neoplasms / epidemiology. Lung Neoplasms / secondary. Lung Neoplasms / therapy. Male. Precursor Cell Lymphoblastic Leukemia-Lymphoma / epidemiology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy. Retinoblastoma / epidemiology. Retinoblastoma / pathology. Retinoblastoma / therapy. Risk Factors. Thyroid Neoplasms / epidemiology. Thyroid Neoplasms / secondary. Thyroid Neoplasms / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Intern Med. 2004 Oct 19;141(8):590-7 [15492338.001]
  • [Cites] N Engl J Med. 1986 May 8;314(19):1201-7 [3702916.001]
  • [Cites] Br J Cancer. 1986 Sep;54(3):483-92 [3756084.001]
  • [Cites] N Engl J Med. 1987 Sep 3;317(10):588-93 [3475572.001]
  • [Cites] Cancer Res. 1991 Jun 1;51(11):2885-8 [1851664.001]
  • [Cites] Lancet. 1991 Aug 10;338(8763):359-63 [1713639.001]
  • [Cites] N Engl J Med. 1991 Nov 7;325(19):1330-6 [1922234.001]
  • [Cites] N Engl J Med. 1991 Dec 12;325(24):1682-7 [1944468.001]
  • [Cites] N Engl J Med. 1992 Mar 19;326(12):781-5 [1538720.001]
  • [Cites] Leukemia. 1995 Dec;9(12):1990-6 [8609707.001]
  • [Cites] J Natl Cancer Inst. 1996 Mar 6;88(5):270-8 [8614005.001]
  • [Cites] J Clin Oncol. 1996 May;14(5):1442-6 [8622057.001]
  • [Cites] JAMA. 1997 Oct 15;278(15):1262-7 [9333268.001]
  • [Cites] Med Pediatr Oncol. 1998 Aug;31(2):91-5 [9680933.001]
  • [Cites] J Natl Cancer Inst. 1998 Sep 16;90(18):1371-88 [9747868.001]
  • [Cites] J Clin Oncol. 1998 Dec;16(12):3761-7 [9850019.001]
  • [Cites] Eur J Cancer. 1998 Dec;34(13):2068-75 [10070313.001]
  • [Cites] Lancet. 1999 Jul 3;354(9172):34-9 [10406363.001]
  • [Cites] AMA Arch Derm Syphilol. 1952 Feb;65(2):123-9 [14884692.001]
  • [Cites] Br J Cancer. 2004 Nov 29;91(11):1905-10 [15534607.001]
  • [Cites] J Clin Oncol. 2005 Jan 1;23(1):197-204 [15625374.001]
  • [Cites] Am J Epidemiol. 2005 Feb 15;161(4):330-7 [15692076.001]
  • [Cites] J Clin Oncol. 2005 Apr 1;23(10):2272-9 [15800318.001]
  • [Cites] Blood. 2005 May 15;105(10):3802-11 [15687239.001]
  • [Cites] Lancet. 2005 May 14-20;365(9472):1687-717 [15894097.001]
  • [Cites] Pediatr Blood Cancer. 2005 Jul;45(1):25-31 [15795880.001]
  • [Cites] J Urol. 2005 Jul;174(1):107-10; discussion 110-1 [15947588.001]
  • [Cites] Lancet. 2005 Jun 11-17;365(9476):2014-23 [15950715.001]
  • [Cites] J Clin Oncol. 2005 Jun 20;23(18):4179-91 [15961765.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Jul 15;62(4):1195-203 [15990025.001]
  • [Cites] Eur J Haematol Suppl. 2005 Jul;(66):68-76 [16007872.001]
  • [Cites] J Natl Cancer Inst. 2005 Jul 20;97(14):1056-66 [16030303.001]
  • [Cites] Blood. 2009 Feb 12;113(7):1408-11 [18974371.001]
  • [Cites] Int J Cancer. 1999 Dec 10;83(6):860-3 [10597212.001]
  • [Cites] Cancer. 2000 Jan 15;88(2):398-406 [10640974.001]
  • [Cites] J Clin Oncol. 2000 Feb;18(3):487-97 [10653864.001]
  • [Cites] J Clin Oncol. 2000 Feb;18(3):498-509 [10653865.001]
  • [Cites] J Clin Oncol. 2000 Apr;18(7):1492-9 [10735897.001]
  • [Cites] Blood. 2000 May 1;95(9):2770-5 [10779419.001]
  • [Cites] J Natl Cancer Inst. 2000 Jul 19;92(14):1165-71 [10904090.001]
  • [Cites] J Clin Endocrinol Metab. 2000 Sep;85(9):3227-32 [10999813.001]
  • [Cites] Lancet. 2000 Sep 9;356(9233):881-7 [11036892.001]
  • [Cites] J Clin Oncol. 2001 Mar 15;19(6):1610-8 [11250989.001]
  • [Cites] BMJ. 1992 Apr 11;304(6832):951-8 [1581717.001]
  • [Cites] N Engl J Med. 1992 Jun 25;326(26):1745-51 [1594016.001]
  • [Cites] J Clin Oncol. 1993 Mar;11(3):485-90 [8383191.001]
  • [Cites] Cancer. 1993 May 15;71(10):3054-7 [8490833.001]
  • [Cites] Lancet. 1993 Jun 5;341(8858):1428-32 [8099139.001]
  • [Cites] J Clin Endocrinol Metab. 1993 Aug;77(2):362-9 [8345040.001]
  • [Cites] J Natl Cancer Inst. 1994 Apr 6;86(7):527-37 [8133536.001]
  • [Cites] Cancer. 1994 Mar 15;73(6):1615-20 [8156488.001]
  • [Cites] J Clin Oncol. 1994 May;12(5):1063-73 [8164031.001]
  • [Cites] J Natl Cancer Inst. 1995 Jan 4;87(1):60-1 [7666469.001]
  • [Cites] Ann Oncol. 2005 Aug;16(8):1343-51 [15905306.001]
  • [Cites] Cancer. 2005 Aug 15;104(4):856-63 [15981282.001]
  • [Cites] J Natl Cancer Inst. 2005 Sep 21;97(18):1354-65 [16174857.001]
  • [Cites] J Natl Cancer Inst. 2005 Oct 5;97(19):1428-37 [16204692.001]
  • [Cites] Lancet. 2005 Dec 17;366(9503):2087-106 [16360786.001]
  • [Cites] J Natl Cancer Inst. 2006 Jan 4;98(1):15-25 [16391368.001]
  • [Cites] J Clin Oncol. 2006 Jan 20;24(3):476-83 [16421424.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2006 Jul 1;65(3):661-8 [16545920.001]
  • [Cites] Cancer. 2006 Sep 1;107(5):991-8 [16878323.001]
  • [Cites] Radiat Res. 2006 Oct;166(4):618-28 [17007558.001]
  • [Cites] Eur J Cancer. 2006 Nov;42(16):2757-64 [16965909.001]
  • [Cites] J Natl Cancer Inst. 2006 Nov 1;98(21):1528-37 [17077355.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2006 Dec 1;66(5):1313-9 [16997501.001]
  • [Cites] J Natl Cancer Inst. 2007 Jan 3;99(1):24-31 [17202110.001]
  • [Cites] Oncologist. 2007 Jan;12(1):20-37 [17227898.001]
  • [Cites] Strahlenther Onkol. 2007 Feb;183(2):57-62 [17294108.001]
  • [Cites] JAMA. 2007 Mar 21;297(11):1207-15 [17374815.001]
  • [Cites] J Clin Oncol. 2007 Apr 20;25(12):1489-97 [17372278.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2007 Jun 1;68(2):359-63 [17379448.001]
  • [Cites] Dermatol Surg. 2007 Jun;33(6):749-55 [17550458.001]
  • [Cites] Cancer. 2007 Jul 1;110(1):31-7 [17510927.001]
  • [Cites] Br J Cancer. 2007 Jul 2;97(1):115-7 [17519906.001]
  • [Cites] Front Radiat Ther Oncol. 2007;40:253-71 [17641514.001]
  • [Cites] Breast Cancer Res Treat. 2007 Dec;106(3):439-51 [17277968.001]
  • [Cites] J Clin Oncol. 2008 Jan 20;26(3):392-8 [18202415.001]
  • [Cites] Br J Cancer. 2008 Mar 11;98(5):870-4 [18268495.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2008 Sep 1;72(1):24-33 [18722263.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2008 Nov 15;72(4):1021-30 [18556141.001]
  • [Cites] J Clin Oncol. 2008 Dec 1;26(34):5561-8 [18854572.001]
  • [Cites] J Clin Oncol. 2001 Jul 1;19(13):3173-81 [11432883.001]
  • [Cites] Cancer. 2001 Jul 1;92(1):172-80 [11443624.001]
  • [Cites] J Natl Cancer Inst. 2002 Feb 6;94(3):182-92 [11830608.001]
  • [Cites] Ann Intern Med. 2002 Mar 19;136(6):463-70 [11900499.001]
  • [Cites] J Clin Oncol. 2002 Apr 15;20(8):2101-8 [11956271.001]
  • [Cites] Blood. 2002 Jun 15;99(12):4257-64 [12036851.001]
  • [Cites] Radiat Res. 2002 Aug;158(2):220-35 [12105993.001]
  • [Cites] J Clin Oncol. 2002 Aug 15;20(16):3484-94 [12177110.001]
  • [Cites] Blood. 2002 Sep 15;100(6):1989-96 [12200357.001]
  • [Cites] Radiother Oncol. 2002 Dec;65(3):145-51 [12464442.001]
  • [Cites] Radiat Res. 2003 Feb;159(2):161-73 [12537521.001]
  • [Cites] Cancer. 2003 Mar 15;97(6):1404-11 [12627503.001]
  • [Cites] J Clin Oncol. 2003 Apr 1;21(7):1195-204 [12663705.001]
  • [Cites] Cancer. 2003 May 15;97(10):2397-403 [12733137.001]
  • [Cites] Blood. 2003 Jul 1;102(1):43-52 [12623843.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2003 Jul 15;56(4):1038-45 [12829139.001]
  • [Cites] J Natl Cancer Inst. 2003 Jul 2;95(13):971-80 [12837833.001]
  • [Cites] JAMA. 2003 Jul 23;290(4):465-75 [12876089.001]
  • [Cites] Br J Cancer. 2003 Sep 1;89(5):840-6 [12942115.001]
  • [Cites] J Clin Oncol. 2003 Sep 15;21(18):3431-9 [12885835.001]
  • [Cites] Cancer. 2003 Oct 1;98(7):1362-8 [14508821.001]
  • [Cites] Cancer. 2003 Oct 1;98(7):1457-64 [14508833.001]
  • [Cites] J Clin Oncol. 2003 Dec 1;21(23):4386-94 [14645429.001]
  • [Cites] J Natl Cancer Inst. 2004 Mar 3;96(5):357-63 [14996857.001]
  • [Cites] Pediatr Blood Cancer. 2004 Jun;42(7):563-73 [15127410.001]
  • [Cites] Br J Cancer. 2004 Aug 31;91(5):868-72 [15292931.001]
  • [Cites] Dermatology. 2004;209(3):175-6 [15459528.001]
  • [Cites] J Clin Oncol. 2009 May 10;27(14):2356-62 [19255307.001]
  • [Cites] J Clin Oncol. 2009 Aug 20;27(24):3901-7 [19620485.001]
  • [Cites] N Engl J Med. 2007 Nov 8;357(19):1916-27 [17989384.001]
  • [Cites] J Clin Oncol. 1999 Jun;17(6):1829-37 [10561222.001]
  • [Cites] J Natl Cancer Inst. 2008 Dec 17;100(24):1771-9 [19066271.001]
  • [Cites] J Clin Oncol. 2009 Jan 1;27(1):52-60 [19047296.001]
  • [Cites] J Natl Cancer Inst. 2001 Apr 18;93(8):618-29 [11309438.001]
  • [Cites] J Clin Oncol. 2001 Jul 1;19(13):3163-72 [11432882.001]
  • (PMID = 19959033.001).
  • [ISSN] 1532-9461
  • [Journal-full-title] Seminars in radiation oncology
  • [ISO-abbreviation] Semin Radiat Oncol
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / / ZIA CP010131-17
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 119
  • [Other-IDs] NLM/ NIHMS526934; NLM/ PMC3857758
  •  go-up   go-down


66. van Grotel M, Meijerink JP, van Wering ER, Langerak AW, Beverloo HB, Buijs-Gladdines JG, Burger NB, Passier M, van Lieshout EM, Kamps WA, Veerman AJ, van Noesel MM, Pieters R: Prognostic significance of molecular-cytogenetic abnormalities in pediatric T-ALL is not explained by immunophenotypic differences. Leukemia; 2008 Jan;22(1):124-31

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Pediatric T-cell acute lymphoblastic leukemia (T-ALL) is characterized by chromosomal rearrangements possibly enforcing arrest at specific development stages.
  • We studied the relationship between molecular-cytogenetic abnormalities and T-cell development stage to investigate whether arrest at specific stages can explain the prognostic significance of specific abnormalities.
  • HOX11 cases were CD1 positive consistent with a cortical stage, but as 4/5 cases lacked cytoplasmatic-beta expression, developmental arrest may precede beta-selection.
  • NOTCH1 mutations were present in all molecular-cytogenetic subgroups without restriction to a specific developmental stage.
  • [MeSH-major] Gene Rearrangement / genetics. Leukemia-Lymphoma, Adult T-Cell / genetics. Neoplasm Recurrence, Local / genetics. Receptor, Notch1 / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17928886.001).
  • [ISSN] 1476-5551
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / AF10-CALM fusion protein, human; 0 / Basic Helix-Loop-Helix Transcription Factors; 0 / Homeodomain Proteins; 0 / NOTCH1 protein, human; 0 / Oncogene Proteins, Fusion; 0 / Proto-Oncogene Proteins; 0 / RNA, Messenger; 0 / RNA, Neoplasm; 0 / Receptor, Notch1; 0 / Receptors, Antigen, T-Cell, alpha-beta; 0 / Receptors, Antigen, T-Cell, gamma-delta; 0 / TLX3 protein, human; 135471-20-4 / TAL1 protein, human
  •  go-up   go-down


67. D'Angelo V, Crisci S, Casale F, Addeo R, Giuliano M, Pota E, Finsinger P, Baldi A, Rondelli R, Abbruzzese A, Caraglia M, Indolfi P: High Erk-1 activation and Gadd45a expression as prognostic markers in high risk pediatric haemolymphoproliferative diseases. J Exp Clin Cancer Res; 2009;28:39
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Studies on activated cell-signaling pathways responsible for neoplastic transformation are numerous in solid tumors and in adult leukemias.
  • The quantitative and qualitative expression and activation of Erk-1, c-Jun, Caspase8, and Gadd45a was analyzed, by immunocytochemical (ICC) and western blotting methods, in bone marrow blasts of 72 patients affected by acute myeloid leukemia (AML), T-cell acute lymphoblastic leukemia (ALL) and stage IV non-Hodgkin Lymphoma (NHL).

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Leukemia. 2000 May;14(5):786-91 [10803507.001]
  • [Cites] Leukemia. 2008 Apr;22(4):686-707 [18337767.001]
  • [Cites] J Clin Invest. 2001 Sep;108(6):851-9 [11560954.001]
  • [Cites] J Cell Biochem. 2002;84(4):675-86 [11835393.001]
  • [Cites] Cancer Res. 2002 Oct 15;62(20):5897-901 [12384554.001]
  • [Cites] Int J Oncol. 2003 Jan;22(1):123-8 [12469194.001]
  • [Cites] Nat Rev Cancer. 2003 Feb;3(2):89-101 [12563308.001]
  • [Cites] Cancer Genet Cytogenet. 2003 Oct 15;146(2):89-101 [14553942.001]
  • [Cites] Leukemia. 2004 Feb;18(2):189-218 [14737178.001]
  • [Cites] Cancer Biol Ther. 2004 May;3(5):470-6 [15034294.001]
  • [Cites] Br J Haematol. 1981 Apr;47(4):553-61 [6938236.001]
  • [Cites] J Natl Cancer Inst. 1999 Aug 18;91(16):1382-90 [10451443.001]
  • [Cites] Oncogene. 1999 Sep 2;18(35):4899-907 [10490824.001]
  • [Cites] Oncol Rep. 2004 Dec;12(6):1201-7 [15547738.001]
  • [Cites] Cancer Res. 2005 Mar 15;65(6):2047-53 [15781610.001]
  • [Cites] Cancer Biol Ther. 2005 Jan;4(1):32-8 [15684603.001]
  • [Cites] Blood. 2005 Jul 15;106(2):408-18 [15797997.001]
  • [Cites] Cancer Res. 2005 Aug 1;65(15):6780-8 [16061660.001]
  • [Cites] Oncogene. 2005 Nov 3;24(48):7170-9 [16170381.001]
  • [Cites] J Biol Chem. 2006 Jun 30;281(26):17552-8 [16636063.001]
  • [Cites] Blood. 2006 Oct 1;108(7):2358-65 [16763210.001]
  • [Cites] Blood. 2007 Jun 15;109(12):5473-6 [17351113.001]
  • [Cites] J Biol Chem. 2001 May 4;276(18):15537-46 [11297525.001]
  • (PMID = 19298651.001).
  • [ISSN] 1756-9966
  • [Journal-full-title] Journal of experimental & clinical cancer research : CR
  • [ISO-abbreviation] J. Exp. Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cell Cycle Proteins; 0 / GADD45A protein, human; 0 / Nuclear Proteins; EC 2.7.11.24 / JNK Mitogen-Activated Protein Kinases; EC 2.7.11.24 / Mitogen-Activated Protein Kinase 1; EC 2.7.11.24 / Mitogen-Activated Protein Kinase 3; EC 3.4.22.- / Caspase 8
  • [Other-IDs] NLM/ PMC2664791
  •  go-up   go-down


68. Bruey JM, Kantarjian H, Ma W, Estrov Z, Yeh C, Donahue A, Sanders H, O'Brien S, Keating M, Albitar M: Circulating Ki-67 index in plasma as a biomarker and prognostic indicator in chronic lymphocytic leukemia. Leuk Res; 2010 Oct;34(10):1320-4
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We recently showed that elevated levels of Ki-67 circulating in plasma (cKi-67) are associated with shorter survival in patients with acute lymphoblastic leukemia.
  • The cKi-67 index showed significant correlation with lymph node involvement and Rai stage (P=0.05).
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biomarkers. Blotting, Western. Female. Humans. Immunohistochemistry. Jurkat Cells. Male. Middle Aged. Prognosis. Proportional Hazards Models. beta 2-Microglobulin / blood

  • Genetic Alliance. consumer health - Chronic Lymphocytic Leukemia.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2010 Elsevier Ltd. All rights reserved.
  • [Cites] J Natl Cancer Inst. 1987 Dec;79(6):1333-40 [3320449.001]
  • [Cites] J Cell Physiol. 2000 Mar;182(3):311-22 [10653597.001]
  • [Cites] J Clin Pathol. 1992 Aug;45(8):660-3 [1401173.001]
  • [Cites] J Clin Oncol. 1993 Oct;11(10):1985-9 [8410123.001]
  • [Cites] N Engl J Med. 1995 Oct 19;333(16):1052-7 [7675049.001]
  • [Cites] Leuk Lymphoma. 1996 Apr;21(3-4):233-8 [8726404.001]
  • [Cites] Cancer Lett. 1997 May 19;115(2):229-34 [9149129.001]
  • [Cites] Ann Oncol. 1997;8 Suppl 1:93-101 [9187440.001]
  • [Cites] Cancer. 1998 Jan 1;82(1):168-75 [9428494.001]
  • [Cites] J Surg Oncol. 1998 Jan;67(1):33-7 [9457254.001]
  • [Cites] Oncol Rep. 1999 Sep-Oct;6(5):1117-22 [10425312.001]
  • [Cites] N Engl J Med. 2005 Feb 24;352(8):804-15 [15728813.001]
  • [Cites] Neoplasma. 2005;52(5):420-4 [16151588.001]
  • [Cites] J Clin Oncol. 2005 Oct 1;23(28):7212-20 [16192605.001]
  • [Cites] Dakar Med. 2005;50(2):65-8 [16295759.001]
  • [Cites] Anticancer Res. 2006 Nov-Dec;26(6C):4873-8 [17214354.001]
  • [Cites] J Natl Cancer Inst. 2007 Jul 4;99(13):1053; author reply 1053-4 [17596578.001]
  • [Cites] Histopathology. 2007 Oct;51(4):491-8 [17711446.001]
  • [Cites] Expert Rev Mol Diagn. 2007 Sep;7(5):615-23 [17892367.001]
  • [Cites] Cancer Chemother Pharmacol. 2008 Apr;61(4):569-77 [17508214.001]
  • [Cites] Cancer Sci. 2008 Aug;99(8):1564-9 [18754867.001]
  • [Cites] Cancer Gene Ther. 2009 Jan;16(1):20-32 [18690204.001]
  • [Cites] Scand J Urol Nephrol. 2009;43(1):12-8 [18949633.001]
  • [Cites] Breast Cancer Res Treat. 2009 Jul;116(1):53-68 [18592370.001]
  • [Cites] Leuk Res. 2010 Feb;34(2):173-6 [19679351.001]
  • [Cites] Histopathology. 1990 Dec;17(6):489-503 [2076881.001]
  • [Cites] Exp Cell Res. 2000 Jun 15;257(2):231-7 [10837136.001]
  • [Cites] Blood. 2002 Oct 15;100(8):2965-72 [12351409.001]
  • [Cites] Rocz Akad Med Bialymst. 2002;47:262-9 [12533969.001]
  • [Cites] Blood. 2003 Apr 1;101(7):2507-13 [12446458.001]
  • [Cites] Int J Cancer. 2003 Jul 10;105(5):710-6 [12740923.001]
  • [Cites] Leukemia. 2003 Jun;17(6):1104-11 [12764376.001]
  • [Cites] Br J Haematol. 2003 Dec;123(5):850-7 [14632776.001]
  • [Cites] Blood. 2004 Apr 1;103(7):2799-801 [14576069.001]
  • [Cites] Cancer. 2004 Sep 1;101(5):999-1008 [15329909.001]
  • [CommentIn] Leuk Res. 2010 Dec;34(12):e326-8 [20723976.001]
  • (PMID = 20362333.001).
  • [ISSN] 1873-5835
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P30 CA016672; United States / NCI NIH HHS / CA / P50 CA100632
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Ki-67 Antigen; 0 / beta 2-Microglobulin
  • [Other-IDs] NLM/ NIHMS593251; NLM/ PMC4108997
  •  go-up   go-down


69. Khamly KK, Thursfield VJ, Fay M, Desai J, Toner GC, Choong PF, Ngan SY, Powell GJ, Thomas DM: Gender-specific activity of chemotherapy correlates with outcomes in chemosensitive cancers of young adulthood. Int J Cancer; 2009 Jul 15;125(2):426-31
Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A detailed substudy of clinical characteristics was analyzed from 179 AYAs with Hodgkin lymphoma (HL), Ewing sarcoma (ES) or osteosarcomas (OS) treated at a single institution.
  • Despite significant improvements in survival for both groups over the period in question, for acute lymphoblastic leukaemia, rhabdomyosarcoma, ES, OS and HL, survival for AYAs was worse than for children.
  • Although no differences in tumor stage or compliance were identified, male AYAs experienced less toxicity and lower response rates to chemotherapy (p = 0.008).
  • [MeSH-minor] Adolescent. Adult. Aged. Female. Humans. Male. Middle Aged. Proportional Hazards Models. Treatment Outcome. Young Adult

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 UICC.
  • (PMID = 19391136.001).
  • [ISSN] 1097-0215
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


70. Sperr WR, El-Samahi A, Kundi M, Girschikofsky M, Winkler S, Lutz D, Endler G, Rumpold H, Agis H, Sillaber C, Jäger U, Valent P: Elevated tryptase levels selectively cluster in myeloid neoplasms: a novel diagnostic approach and screen marker in clinical haematology. Eur J Clin Invest; 2009 Oct;39(10):914-23
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • MATERIALS AND METHODS: We have determined serum tryptase levels in 914 patients with haematological malignancies, including myeloproliferative disorders (n = 156), myelodysplastic syndromes (MDS, n = 241), acute myeloid leukaemia (AML, n = 317), systemic mastocytosis (SM, n = 81), non-Hodgkin's lymphoma (n = 59) and acute lymphoblastic leukaemia (n = 26).
  • In most patients with non-neoplastic haematological disorders and non-haematological disorders analysed in our study, tryptase levels were normal, the exception being a few patients with end-stage kidney disease and helminth infections, in whom a slightly elevated tryptase was found.
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Biomarkers / metabolism. Child. Child, Preschool. Female. Humans. Immunohistochemistry. Male. Middle Aged. Tryptases / genetics. Young Adult

  • MedlinePlus Health Information. consumer health - Myelodysplastic Syndromes.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19522836.001).
  • [ISSN] 1365-2362
  • [Journal-full-title] European journal of clinical investigation
  • [ISO-abbreviation] Eur. J. Clin. Invest.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers; EC 3.4.21.59 / Tryptases
  •  go-up   go-down


71. Holowiecka-Goral A, Hołowiecki J, Giebel S, Stella-Holowiecka B, Krawczyk-Kulis M, Kos K, Lehmann-Kopydłowska A, Dudzinski M, Hałasz M, Preisner W, Cioch M, Piszcz J: Liposomal cytarabine in advanced-stage acute lymphoblastic leukemia and aggressive lymphoma with central nervous system involvement: experience of the Polish Acute Leukemia Group. Leuk Lymphoma; 2009 Mar;50(3):478-80
Hazardous Substances Data Bank. CYTARABINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Liposomal cytarabine in advanced-stage acute lymphoblastic leukemia and aggressive lymphoma with central nervous system involvement: experience of the Polish Acute Leukemia Group.
  • [MeSH-major] Central Nervous System Neoplasms / drug therapy. Cytarabine / administration & dosage. Lymphoma / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Drug Carriers. Female. Humans. Liposomes. Male. Middle Aged. Poland. Remission Induction. Treatment Outcome. Young Adult

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Lymphoblastic lymphoma.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19294561.001).
  • [ISSN] 1029-2403
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Drug Carriers; 0 / Liposomes; 04079A1RDZ / Cytarabine
  •  go-up   go-down


72. Hudson MM: Achieving cure for early stage pediatric Hodgkin disease with minimal morbidity: are we there yet? Pediatr Blood Cancer; 2006 Feb;46(2):122-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Achieving cure for early stage pediatric Hodgkin disease with minimal morbidity: are we there yet?
  • [MeSH-major] Antimetabolites, Antineoplastic / administration & dosage. Deoxycytidine / analogs & derivatives. Leukemia, Myeloid, Acute / prevention & control. Precursor Cell Lymphoblastic Leukemia-Lymphoma / prevention & control
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Disease-Free Survival. Female. Humans. Infant. Male. Recurrence. Treatment Failure

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] Pediatr Blood Cancer. 2006 Feb;46(2):198-202 [16136581.001]
  • (PMID = 16261587.001).
  • [ISSN] 1545-5009
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 21765
  • [Publication-type] Comment; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine
  •  go-up   go-down






Advertisement